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ABSTACT 
Colorectal cancer (CRC) is not a homogenous disease. Recent molecular 
classification of established tumours based on gene expression and (epi)genetic 
mutation burden, has revealed considerable disease heterogeneity. The relative 
importance of the epithelial and stromal tissue compartments varies between 
different tumour subtypes and this contributes to the observed clinical and 
molecular heterogeneity of CRC. 
The AIM of this study was to explore the role of the stroma in different 
precancerous pathologies (polyps) and in CRC.  
Stromal gene expression varies considerably between the different polyp 
subtypes (SSA and TVA) with a comparatively greater number of differentially 
expressed genes in serrated lesion stroma, suggesting the hypothesis that SSA 
lesions, usually initiated by BRAF mutations and methylation, require the 
recruitment of pro-tumorigenic stroma to enable lesion progression. In contrast, 
TVA are initiated by epithelial mutations that disrupt Wnt signaling (such as 
APC) and this is sufficient to drive tumourigenesis, irrespective of stromal 
influences.  
Moreover, transwell tissue culture 3D techniques and animal models revealed 
that fibroblasts support the cross species growth of mouse epithelial organoids 
and abrogate the normal media requirement for Noggin and EGF. Interestingly, 
mouse epithelium grown in this co culture system develop as spheroids rather 
than the branching organoids seen with media morphogen supplementation, 
indicating a phenotype modulating effect of the fibroblasts.  
Preliminary results revealed that fibroblasts have effects on cell proliferation 
and cell cycle regulation by upregulation of genes involved with cell cycle 
progression, DNA synthesis/repair, protein translation, vesicles mediated 
transport and lipid metabolism.  
Primary stromal cell cultures isolated from adenoma and colon cancer (CMS2 
and CMS4) might in part represent the corresponding cancer 
microenvironment, thus providing a useful complement to the current cellular 
biochemistry and therapeutic research in CRC.  
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SOMMARIO 
Il cancro del colon-retto (CRC) non è una malattia omogenea. Una recente 
classificazione molecolare sul CRC basata sull’ espressione genica e 
mutazioni (epi)genetiche, ha rivelato una notevole eterogeneità nella  
malattia. L'  importanza dei compartimenti tissutali, epitelia liali e 
stromali, varia tra i diversi sottotipi di CRC e questo contribuisce all’  
eterogeneità clinica e molecolare osservata nel CRC. 
Lo scopo di questo studio è stato quello di esplorare il ruolo dello stroma 
in diverse forme pretumorali (polipi) e nel CRC.  
Dalle analisi eseguite,  e’ emerso che il profilo genetico dello stroma nelle 
due condizioni pre cancerogene di CRC oggetto di studio (TVA e SSA),  
differisce in maniera significativa, suggerendo l’ipotesi che i polipi di 
tipo SSA, in genere promossi da mutazioni nel gene BRAF, richiedono 
l'assunzione di stroma pro-cancerogeno per consentire la progressione 
della lesione. Al contrario, in lesioni di tipo TVA, le mutazioni epiteliali 
che interrompono la via di segnalazione Wnt (es. APC), siano sufficienti 
per promuovere la tumorigenesi a prescindere dall’ influenza dello 
stroma.  
Inoltre, con l’ausilio di t ecniche di coltura 3D, insert i e modelli animali,  
e’ emerso che i fibroblasti sostengono la crescita degli organoidi murine 
senza l’impiego dei fattori di crescita  Noggin e EGF. In particolare,  i 
fibroblasti causano lo sviluppo di sferoidi piuttosto che di organoidi,  
indicando un effetto modulante sul fenotipo.  
I risultati preliminary, hanno rivelato che i fibroblasti hanno effett i sulla 
proliferazione cellulare e la regolazione del ciclo cellulare mediante la  
regolazione in maniera posit iva dei geni coinvolti nella progressione del 
ciclo cellulare, nella sintesi e/o r iparazione del DNA, nella traduzione di 
proteine, nel trasporto mediato da vescicole e nel metabolismo dei lipidi.  
I fibroblasti isolati da adenoma e CRC (CMS2 e CMS4) potrebbero in 
parte rappresentare il microambiente tumorale, fornendo così un utile 
complemento biochimico e cellulare sulla ricerca terapeutica nel tumore 
del colon.  
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1. INTRODUCTION 
 
1.1    Structure of the colon and rectum  
1.1.1 Anatomy and physiology 
The colon is an abdominal organ, covered by the peritoneum except 
for the most distal part, the rectum; its length is in the order of 100 
to 150 cm beginning in the ileocecal valve and ending in the 
anorectal junct ion (Ponz de Leon & Di Gregorio 2001).  
The large bowel can also be categorized by the regions of vascular 
supply. “The right colon” (from caecum to splenic flexure) is 
supplied by the branches of the superior mesenteric artery, while the 
inferior mesenteric artery feeds “the left  colon” (descending and 
sigmoid colon). The blood supply to the lower rectum is delivered 
by the branches of the internal iliac artery, the middle and inferior 
rectal arteries, and this third anatomical region is called “the 
rectum”.  
The colorectal mucosa is covered by two layers of circular and 
longitudinal smooth muscle cells, which are adjacent to serosa and 
subserosal t issues; contract ion of the external longitudinal muscle 
layer accounts for the appearance of character ist ic haustrations 
along the colon (Ponz de Leon & Di Gregorio 2001) (Figure 1).  
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Figure 1. The anatomical subdivision of the large bowel. Adapted from Encyclopaedia 
Britannica 2003. 
 
 
1.1.2 Histological structure 
The normal colorectal mucosa is const ituted by 3 main elements: 
epithelium (of the surface and crypts), lamina propria and 
muscularis mucosae; the latter separates the mucosa from the deeper 
submucosa (Figure 1).  
The colonic surface epithelium is composed of a single layer of 
columnar cells which funct ion as a protective barrier between host 
and luminal environment. The two main cellular elements of the 
epithelium are absorptive cells (responsible for ion and water 
absorption) and goblet cells (which synthesize, store and secrete 
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mucin); a thin basement membrane (composed of collagen and other 
proteins) anchors and supports the surface epithelium.  
A similar single-layer columnar cell epitheliurn forms the colorectal 
crypts; besides absorptive and goblet cells, crypt epithelium also 
contains undifferent iated precursor cells, specialised endocrine cells 
(containing secretory granules) and rare Paneth cells (pyramid -
shaped cells containing eosinophilic secretory granules, the funct ion 
of which remains unclear), especially in the proximal colon.  
The lamina propria extends between crypts and reaches the 
muscularis mucosae and it contains a wide variety of cells, including 
fibroblasts, lymphocytes, plasma cells, eosinophils,  macrophages 
and mast cells, which are arranged among strands of collagen tissue.  
Colonic mucosa also contains well formed gut -associated lymphoid 
tissue which is responsible for local defence against harmful agents 
originat ing in the gut lumen (Intest inal immunity and inflammation: 
recent progress 1986).  
The muscularis mucosae is a thin layer of smooth muscle which 
separates the epithelium and lamina propria from the submucosa. 
Contraction of the muscularis may alter the shape of the mucosa, 
thus affect ing normal physiologic processes (absorption of water and 
electrolytes, mucin secret ion, cell replicat ion).  
The submucosa is const ituted by the same elements that feature the 
lamina propria (such as lymphocytes that  can form lymphat ic 
follicles, fibroblasts, macrophages, mast cells and fibrous t issues).  
Two neural plexuses are located in the submucosa; one immediately 
beneath the muscularis mucosae (Meissner plexus), the other 
(Auerbach plexus) lies in the deeper part of the submucosa, close to 
the lamina propria. Vascular elements of the submucosa include 
arterioles, venules and lymphat ic vessels; these submucosal 
structures may, sometimes, appear larger or tortuous even in the 
absence of any colonic abnormality (Ponz de Leon & Di Gregorio 
2001).  
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1.1.3 Intestinal architecture 
1.1.3.1 Intestinal stem cells  
The normal colon has two dist inct pools of stem cells, which 
together make up the total populat ion of 16 stem cells (Medema & 
Vermeulen 2011, Vaiopoulos et al. 2012, Stange & Clevers 2013).  
The contribut ion of each pool to the total is not known. The first 
stem cell pool is localized in the crypt base (crypt base columnar 
cells (CBCs) and can be characterized by high LGR5 (Leucine-rich 
repeat containing G protein-coupled receptor) expression and is 
largely comprised of a proliferat ing population (Barker et al.  2007, 
Kemper et al. 2010). The next pool is nearby in the +4 posit ion of 
the colon base (four cells away from the base of the crypt) and 
consists of relat ively quiescent or dormant cells. This second pool 
exhibits high expression of BMI-1 (Polycomb complex protein) and 
telomerase reverse transcriptase (TERT) (Medema & Vermeulen 
2011, Bertrand et al. 2012). 
Regulat ion of normal intest inal stem cells occurs at the crypt base,  
in particular, in the stem cell niche. The stem cell niche consists o f 
epithelial, mesenchymal cells and extracellular substrates which 
favour the existence of a stem cell in its undifferent iated state. It 
provides an opt imal microenvironment for the production of 
different iated progeny by the paracrine secretion of growth factors, 
cytokines, and morphogens. The phenotypic response of a cell is 
determined by its posit ion within these concentration gradients. Key 
const ituents of the niche include Paneth cells and pericryptal 
fibroblasts. 
Stem cells at the crypt base produce rigorously dividing transit -
amplifying cells. While proliferat ing, transit -amplifying cells move 
upward and reach the crypt -villus junct ion after four to five cell 
divisions, after which they fulfill their specific funct ion as 
specialized cells (Heath 1996).  To compensate the cont inuous, 
conveyor-belt-like flow of cells along the crypt -villus axis, cells at 
the villus tip undergo apoptosis and are shed into the gut lumen. 
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This cont inuous renewal of the epithelium along the vert ical (crypt -
to-luminal surface) axis of the intest ine happen within the 5–7 days 
that it  takes for a cell to migrate from the crypt base to the lumina l 
surface (Biswas et al. 2015). Only one cell type, the Paneth cell,  
escapes this upward movement. Pushed downward by the repulsive 
forces of Ephrins (Eph receptor-interacting proteins) and their 
Ephrin type-B (EphB) receptors, Paneth cells settle at the very base 
of crypts (Bat lle et al. 2002) (Figure 2).  
Adult  stem cell and daughter cell fate determinat ion is controlled by 
the same signalling pathways that regulate embryonic ste m cell 
funct ion during development. In the adult, these pathways are 
stringent ly controlled with complex interact ions used to restrict 
pathway act ivity and response to the appropriate cell compartment.  
Mesenchymal and epithelial-derived pathways result in polarized 
gradients that regulate stemness, cell proliferat ion, different iat ion, 
and apoptosis as cells progress along the intest inal vert ical axis.  
Important pathways include Wnt, BMP, Hedgehog (HH), and Notch 
signaling (Biswas et al. 2015).  
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Figure 2. Intestinal crypt architecture and cell types. The intestinal crypt is the basic 
functional unit of the gut. In the small intestine, several crypts contribute to finger-like 
projections called villi. In homeostasis, the stem cells (crypt base columnar and +4 cells) are 
restricted to the crypt base stem cell niche. Immediate stem cell progeny divide rapidly in the 
bottom half of the crypt, called the transit amplifying zone. Terminal differentiation occurs in 
the upper part of the crypt, with fully differentiated cells eventually being shed into the 
intestinal lumen. Under homeostatic conditions in the mammalian gut, transit along the crypt–
luminal axis takes 5–7 days . From Biswas et al. 2015.  
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The gut is subdivided anatomically into two parts, the small 
intest ine and the colon.   
 
1.1.3.2 Small Intestine 
The small intest ine’s surface is maximized by millions of 
protrusions of the epithelium, called villi and by invaginat ions into 
the submucosa, called crypt of Lieberkuhn. They are composed of 
colon stem cells, transit amplifying cells and terminally 
differentiated goblet cells, enterocytes and endocrine cells  
(Medema & Vermeulen 2011). Each normal crypt is comprised of 
about 2,000 cells (Vaiopoulos et al . 2012).  
 
1.1.3.3 Colon 
While having an overall similar setup, the colon differs from the 
small intest ine by the absence of villi,  creat ing a flat surface 
epithelium. While typical Paneth cells are missing in the colon, 
deep-crypt-secretory cells have been proposed to represent their 
colonic counterpart. Colonic transamplifying cells different iate 
toward the goblet and absorptive cell lineages (Altmann 1983).  
Similar to the crypt of the small intestine, less differentiated 
cells reside in the bottom and terminally different iated cells reside 
near the top (Bertrand et al. 2012).  
 
1.2 Colorectal premalignant lesions  
Colorectal polyps encompass a range of lesions, widely defined as 
mucosal protrusions and tumor-like lesions in the large intest ine. In 
addit ion to premalignant epithelial lesions (CAs and serrated 
adenomas) and hyperplast ic polyp (HPs), the definit ion also includes 
inflammatory and react ive polyps (e.g. mucosal prolapse-associated 
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polyp, inflammatory pseudo-polyp and infect ion-associated polyp), 
hamartomatous polyps (e.g. Peutz-Jeghers polyp and Juvenile 
polyp), stromal polyps (e.g.inflammatory fibroid polyp, Schwann 
cell hamartoma, and lipoma), lymphoid polyps (e.g. prominent  
lymphoid follicles and lymphomatous polyposis), endocrine polyps 
(e.g. well different iated endocrine tumor) and other lesio ns (e.g.  
prominent mucosal fold, elastotic polyp and endometriosis) 
(Hamilton et al. 2010, Snover et al. 2010). The epithelial polyps are 
discussed subsequent ly in more detail because of the biological 
cont inuum between these lesions and colorectal adenocarcinoma 
(CRC). 
 
1.2.1 Aberrant crypt foci  
Aberrant crypt foci (ACF), comprising only a few colonic crypts, are 
the earliest microscopically dist inguishable lesions preceding the 
development of CAs and SPs. ACF were first described in the 
colorectum of experimental rodent models exposed to carcinogens,  
and soon after this,  in human colonic epithelium (Pret low et 
al.1991). Different types of ACF can be histologically characterized. 
Heteroplast ic/hyperplast ic type (ACF-H) and serrated type crypt foci 
(ACF-S) share morphological and molecular similarit ies with SPs 
whereas dysplast ic aberrant crypt foci (ACF-D) have a resemblance 
with miniature CAs. The term “microadenoma” includes ACF with 
dysplasia. Macroscopically, ACF can be detected in colonoscopy 
only with magnifying chromoendoscopy or other similar techniques 
because of the minute non-polypoid structure (Inoue et al. 2014, 
Mäkinen 2007, Rosenberg et al. 2007).  
 
1.2.2 Conventional colorectal polyps (CAs)  
In a recent ly published prospect ive population-based colonoscopy 
study on 745 individuals, 10% had adenomas, and 95% of them were 
CAs (Forsberg et al.  2012). It has been reported that the five -year 
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incidence rate of adenomas after a negat ive screening colonoscopy 
is approximately 15% (Imperiale et al. 2009).  
CAs can be classified into tubular (TA), tubulovillous (TVA) and 
villous adenomas (VA) and represent the most often encountered 
precursor lesions of the CRC, defined by epithelial dysplasia 
varying from low to high grade (Buda et al. 2012, Carr et al. 2009).  
They are more common in males and in patients aged 50 years or 
more (Hetzel et al. 2010, Neugut et al. 1993, Pendergrass et al.  
2008). Most of them are <1 cm in size and macroscopically polypoid 
or sessile less frequent ly flat or depressed (Hamilton et  al.  2010, 
Rembacken et al. 2000). Increasing adenoma size has been reported 
to associate with synchronous and metachronous adenomas (Mattar 
& Rex 2008), as well as with malignant change (O’Brien et al. 1990, 
Shinya & Wolff 1979). In addit ion to large size  of the lesions,  
extensive villous architecture, high-grade epithelial dysplasia 
(named “advanced adenoma”) and flat structure have been shown to 
increase the tendency toward malignant disease (Hamilton et al.  
2010).  
The histological appearance of TA is tubular crypts that usually 
stand closer to each other than in normal mucosa. Villous 
architecture, defined as leaf- or finger-like project ions of the 
colorectal epithelium, does not represent more than 20 to 25% of the 
polyp size.  
TVAs are formed of a mixture of tubular and villous architectures 
containing at least 25% villous structures, while VAs are mainly 
(>75%) comprised of them. All the CAs contain intraepithelial 
dysplasia (“convent ional adenomatous dysplasia”) characterized by 
increasing cellularit y, the loss of polarity and the stratificat ion of 
enlarged, pleomorphic (possibly oval or vesicular) nuclei with 
increased mitotic act ivity and reduced mucin (Hamilton et al. 2010, 
Konishi & Morson 1982).  
Flat adenoma (FA) is a rare variant of CA init ially thought to be 
unique to Japanese populat ion but current ly known to occur also in 
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Western populat ion (Rembacken et al.  2000). Histologically, FAs 
are usually slight ly elevated (<2 mm in height), less frequent ly 
completely flat or even depressed, making the ir detect ion extremely 
difficult in colonoscopy without special dyeing (methylane blue,  
cresyl or crystal violet and indigo carmine have all been described). 
Despite the small size of these lesions, they often show high-grade 
dysplasia or even harbor invasive cancer, giving ground for the 
hypothesis of these lesions being behind the “de novo” CRCs (Kudo 
et al. 2008, Rembacken et al. 2000).  
 
1.2.3 Serrated colorectal polyps 
Serrated polyp of the large intest ine, unt il recent ly, was recognized 
as a common benign lesion, with the small innocuous hyperplast ic 
polyp (HP) as the prototype.  
The morphologic complexity of the serrated adenoma varies from 
being clearly adenomatous to being difficult to dist inguish from 
hyperplast ic polyp, which creates a need for more detailed 
morphologic analysis of all serrated polyps.  The suggest ion has been 
made to eliminate the term “hyperplast ic polyp” altogether and 
simply designat ing these lesions as “serrated polyps” (Iino et al.  
1999). SPs represent 35–40% of the colorectal polyps and are 
classified into Hyperplast ic polyp (HP), sessile serrated adenoma 
(SSA) and tradit ional serrated adenoma (TSA).  
 
Hyperplastic polyp  
Hyperplast ic polyp (HP) is the most common SP, account ing for 
approximately a quarter to a third of all resected colorectal polyps 
(Carr et al. 2009, Higuchi et al. 2005, Spring et al. 2006).  
Macroscopically, HPs are typically small, flat epithelial lesions that 
rarely reach >1 cm in size. Proximal HPs, which are usually larger 
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than distal ones, can be covered by a yellow mucus cap that can 
impede their detect ion in colonoscopy (Snover et al. 2010). It lacks 
dysplast ic architectural distortion and mutagenic potential for 
transformation to cancer, and does not represent risk for developing 
neoplasia (Laiyemo et a l. 2009). Management of HP involves at  
most confirmat ion by biopsy on colonoscopy.  
The histologic appearance of HP is symmetrical, vert ically oriented, 
slender crypts with saw-tooth epithelial serrations generally limited 
to the superficial half of the crypt. The subepithelial basement  
membrane and muscularis mucosae are thickened compared with 
adjacent normal mucosa or the collagen layers of other SPs and the 
amount of endocrine cells at crypt bases may be slight ly increased 
(Mäkinen 2014). The expanded proliferat ive zone typically locates 
symmetrically in the crypts’ bases, while the maturat ion zone is 
evenly and symmetrically distributed in the luminal compartment 
(Torlakovic et al. 2008). There are subt le variat ions in the polyp 
locat ion in the colorectum, histology and mutation rates between the 
different subtypes of HPs.  
Microvesicular HPs are the most common subtype represent ing 
approximately 70% of HPs, encountered mainly in the distal colon 
and rectum, and largely carrying BRAFV600E mutation (Burnet t-
Hartman et al. 2013, Spring et al. 2006, Yang et al. 2004). The most  
designated histological feature among microvesicular HPs are small 
mucin droplets in the cytoplasm (“microvesicular”) of epithelial 
cells with varying amounts of goblet cells in between (Mäkinen 
2014). Based on the similar histology and the frequencies o f 
BRAFV600E mutation, microvesicular HPs and SSAs are hypothesized 
to form a biological cont inuum (Bettington et al. 2013).  
Goblet-cell rich HPs are predominant ly located in the distal colon 
and rectum and frequent ly (in approximately half of the cases) 
harbor the KRAS (Kirsten rat sarcoma viral oncogene homolog) 
mutation (Spring et al. 2006, Yang et al. 2004). Serration is often 
less conspicuous compared with microvesicular HPs and more 
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strict ly limited to the upper parts of the crypts abundant in goblet  
cells. There is lack of evidence of goblet -cell rich HPs being able to 
progress to CRC (Bettington et al. 2013, Mäkinen 2014).  
Mucin-poor HPs are the most infrequent ly encountered subtype  of 
HPs. It has been suggested that they more likely represent  
microvesicular HPs with degenerat ive features than a dist inct ent ity.  
Fine saw-tooth epithelium is present in microvesicular HPs as in 
other HPs, but the loss of goblet cells and microvesicular  mucin, as 
well as the degenerat ive changes in remaining cells, separate the 
polyp from other subtypes (Mäkinen 2014).  
 
Sessile serrated adenoma  
In 1996, Torlakovic & Snover ident ified a subset of serrated lesions 
within “hyperplast ic polyposis”, displaying an abnormal architecture 
without cytological dysplasia and defined them as “sessile serrated 
adenomas” (SSA) (Torlakovic & Snover 1996), which are now 
considered as precursors of microsatellite unstable colorectal 
carcinomas (Leedham et al. 2005).  
SSAs are sessile or flat, rarely pedunculated, lesions with 
unobtrusive borders and smooth surface, often covered with mucus 
(Kim et al. 2013, Mäkinen 2014). Their average size is larger than 
HPs but the sessile structure, as well as the often pale -appearing or 
slight ly reddish surface epithelium, makes their detect ion difficult  
during colonoscopy (Snover et al. 2010).  A similar surface, with 
stellate, wide crypt openings (‘stellate pit pattern’), is often detected 
in SSAs and microvescicular HPs (Hasegawa et al. 2011, Kimura et  
al. 2012).  
The est imated proportion of SSAs among colon polyps has varied 
great ly in previous colonoscopic series and the inter-observer 
variability of the diagnosis of SSA has been considerable in past  
studies (Farris et al. 2008, Hetze l et al. 2010, Rau et al. 2014). 
However, in recent ly published demographic studies, SSAs were 
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reported to represent 1.7–11.7% of all colon polyps (approximately 
a quarter of SPs) and typically, to have a predilect ion for the 
proximal colon (Carr et al. 2009, Higuchi et al. 2005, Lash et al.  
2010, Spring et al. 2006) and female gender (Carr et al. 2009, Lash 
et al. 2010, Spring et al. 2006).  
Crypt compartmentalizat ion aberrat ion, the dispersed, asymmetrical 
proliferat ive zone situated on one or the other side of the crypts and 
extending to the bottom of the crypts, characterizes the architectural 
disorganizat ion in SSAs. Prominent epithelial serrat ion lining the 
crypts’ sides extends deep into the bottom of the basally dilated, J -,  
L- or inverted T-shaped crypts. Irregular crypt branching and 
pseudoinvasion of the crypts beneath the muscularis mucosae, as 
well as subt le nuclear atypia (vesicular, oval-shaped nuclei with 
prominent nucleoli), possibly mitoses dispersed anywhere in the 
crypt epithelium, dystrophic, irregularly distributed goblet cells and 
excessive mucin product ion are also often encountered in SSAs 
(Hamilton et al. 2010, Mäkinen 2014, O’Brien et al. 2008).  
SSAs often harbor BRAFV600E mutat ion (Jass et al. 2006, Kambara et 
al.2004, Spring et al. 2006). It is important to stress that SSAs share 
this molecular feature with microvesicular -hyperplast ic polyps 
which have led Yang et al. to suggest that SSAs may have evolved 
from this type of hyperplast ic polyps (Yang et al. 2004, Bauer & 
Papaconstant inou 2008). Moreover, BRAF mutat ion is strongly 
linked with CIMP-high SSAs or sporadic MSI-high colorectal 
cancers, as shown by Kambara et al.2004 (Kambara et al.2004). As 
BRAF mutat ion and CIMP have been ident ified in the earliest 
serrated lesions (microvesicular-hyperplastic polyps, SSAs without 
dysplasia) they are presumed by experts to be the init ial stages of 
the serrated pathway (Mercer & Pritchard CA 2003).  
Silencing of the DNA (deoxyribonucleic acid) mismatch repair 
(MMR) gene mutL homolog 1 (MLH1) as a consequence of 
methylat ion of the CpG (cytosine-phospho-guanine) islands in the 
promoter area of the gene is another well characterized and 
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documented feature that may eventually lead to progression into a 
lesion with cytological dysplasia (Bettington e t al. 2013,Mäkinen 
2014).The loss of funct ion of hMLH-1 through hyper-methylat ion of 
its promoter region is thought to be a later event along this sequence 
with a higher risk of progression to cancer as suggested by the 
strong prevalence of hMLH-1 methylat ion in SSAs with cytological 
dysplasia (Calon et al 2015, Isella et al. 2015, De Sousa et al. 2013).  
 
Sessile serrated adenoma with dysplasia  
Two types of cytological dysplasia have been reported to occur in 
approximately 15% of SSAs (Lash et al. 2010, Teriaky et al. 2012),  
giving these polyps the name “SSA with cytological dysplasia” 
(SSA-D) in the WHO classificat ion (Snover et al. 2010). The 
convent ional adenomatous dysplasia is the same type of epithelia l 
dysplasia as seen in CAs and, in addit ion to be ing seen in some 
SSAs, it  is more frequent ly encountered in TSAs (Bettington et al.  
2013, Fujita et al. 2011, Kim et al. 2010). Another type of dysplasia 
in SSAs is “serrated dysplasia” defined as cells with abundant 
eosinophilic cytoplasm and basally located vesicular nuclei.  Nuclear 
piling is not as evident as in convent ional adenomatous dysplasia 
and the serrated architecture is typically retained (Mäkinen 2014).  
 
Traditional serrated adenoma  
In 1990, Longacre and Fenoglio-Preiser noticed that some “serrated” 
polyps shared features with both convent ional adenomas and 
hyperplast ic polyps and thereby coined these polyps “tradit ional 
serrated adenomas” (TSAs) (Longacre & Fenoglio-Preiser 1990).  
TSAs comprise approximately 1–2% of SPs (Buda et al. 2012, Carr  
et al. 2009).  
Macroscopically, they have been reported to most ly have a 
protuberant reddish appearance resembling pine cone or coral reef or 
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a two-tiered appearance and thus, to be structurally closer to CAs 
than other SPs (Mäkinen 2014, Snover et al. 2010). Sessile 
appearance, especially in proximal TSAs, is also encountered 
(Hasegawa et al. 2011, Rex et al. 2012) and in some studies, even 
more frequent ly than polypoid appearance (Kim et al. 2013, Wiland 
et al. 2014). They can be located in any part of t he large bowel with 
a slight predilect ion for the distal colon and rectum (Bettington et 
al. 2014, Fu et al. 2012, Wiland et al. 2014).  
Histologically, TSAs are typically characterized by tubulovillous 
structures, eosinophilic, tall columnar cells with pen icillate nuclei 
forming the epithelium with prominent serration and a mixture of 
variable amounts of goblet cells. Other cytological features include 
central, elongated nuclei, mild pseudostratificat ion, and eosinophilic 
cytoplasm (Harvey & Ruszkiewicz 2007). Abnormally developed, 
small nest-like structures, ectopic crypt foci (ECF), are often 
dispersed along the epithelial cells (Mäkinen 2014). They lose the 
orientat ion toward muscularis mucosae but maintain the orientation 
toward the mucosal surface of the bowel lumen, thus leading to 
speculat ions about ECF’s possibly reflecting the disturbances o f 
epithelial-mesenchymal interact ions (Bettington et al. 2013, Haramis 
et al. 2004). Furthermore, ECF are hypothesized to explain the 
biological basis of protuberant growth in TSAs and they are 
regarded as the most characterist ic histological feature for them, 
rarely present in any other colon polyps (Haramis et al. 2004, Rex et 
al. 2012, Snover et al. 2010).  
The overall proliferat ive act ivity in TSAs is significant ly lower 
compared with CAs and has been reported to have two types o f 
manifestations with either a preferent ial location in ECF or irregular 
distribut ion throughout the intervening surface epithelium (Fu et al.  
2012, Kim et al. 2013, Torlakovic et al. 2008). 
As SSAs, TSAs show two types of epithelial dysplasia,  serrated and 
convent ional, of which convent ional adenomatous dysplasia is also 
frequent ly (in up to 49% of TSAs) encountered (Bettington et al.  
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2014, Fu et al. 2012, Kim et al. 2010). Act ivat ing mut at ions in 
either BRAF or KRAS oncogenes frequent ly occur in TSAs 
(Bettington et al. 2014, Fu et al. 2012, Kim et al. 2010, Wiland et al.  
2014).The molecular features of the TSA are less  well established 
but include KRAS mutations and aberrant methylat ion with 
hypermethylat ion of the promoter of MGMT (methylguanine DNA 
methyltransferase) (Landis et al. 1998).  
 
Overlapping features of serrated polyps  
Despite the carefully defined histological characterist ics, the 
classificat ion of different colorectal polyps can be challenging due 
to the overlapping features between the different polyps. The 
dist inct ion between morphologically reminiscent microvesicular HP 
and SSA is mainly based on the disordered growth in the lower 
crypts with a consequence of irregular branching and J-, L- or 
inverted T-shaped crypts lined by epithelial serration. Whether just  
one irregular crypt is sufficient for the change of microvesicular HP 
diagnosis to SSA is undefined (Bateman 2014, Bettington et al.  
2014). Furthermore, high-grade dysplast ic or carcinomatous areas in 
SSAs do not always show serrated structure but principally CA-like 
tubular or tubulovillous structures, despite harboring the same 
molecular changes that are typical of early SSAs (Fujita et al. 2011, 
Goldstein 2006).  
ECF were regarded as a specific histological feature of TSAs. 
However, ECF have recent ly been reported to be encountered also in 
TVAs, indicat ing a histological overlap between serrated and 
convent ional colon polyps (Hafezi- Bakht iari et al. 2015). Moreover,  
the oncocyt ic-like cells, formerly associated with the presence of 
ECF and characterized by the deeply eosinophilic, abundant 
cytoplasm and elongated nuclei, were also reported to occur in other 
types of colon polyps, both serrated and convent ional ones,  
highlight ing the problems of too straightforward categorizat ions 
(Snover 2011).  
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Although epithelial serration is thought to be the most characterist ic 
feature of SPs, also TVAs have been reported to contain focal areas 
of epithelial serrat ion. These polyps have been suggested to be 
named as TVAs with serrat ion (sTVAs) (Bettington et al. 2013, Tsai 
et al. 2014). Moreover, a recent ly published study indicated sTVAs 
being larger, more often proximal, more histologically advanced, 
and showing more frequent CpG island methylat ion and higher 
numbers of KRAS mutation compared with convent ional TVAs. 
Compared to TSAs, they were more often proximal, showed less 
CpG island methylat ions, more frequent MGMT (O-6 
methylguanine-DNA methyltransferase) methylat ion and more 
frequent nuclear translocat ion of β-catenin (Bettington et al. 2016).  
What the histological similarit ies tell about the background of 
different colorectal polyps is somewhat undetermined. Some 
recent ly published studies have shown that TSAs fairly often co ntain 
areas resembling HPs and SSAs within one polyp, a phenomenon 
that is possibly thought to reflect the biological cont inuum within 
the serrated group of colorectal polyps (Bettington et al. 2014, Kim 
et al.2010, Kim et al. 2013, Wiland et al. 2014).  
 
Risk of malignancy in serrated polyps  
In general, HPs, especially when present in mult iple numbers in the 
rectum, are considered to be innocent lesions without the ability to 
malignant progression and are thus infrequent ly sampled (Bettington 
et al. 2013, Mäkinen 2014). However, the est imated share of 30–
35% of CRCs originat ing via the serrated pathway forms a sharp 
contrast to the reported low prevalence numbers of SSAs, SSA-Ds 
and TSAs (Mäkinen 2014). Whether this inconsistency tells about 
the higher risk of malignancy in serrated precursor lesions, their 
poor recognit ion in endoscopy or light microscopy, or the shortened 
time frame for detect ion due to the SPs’ faster growth rate to CRC, 
is ambiguous (Mäkinen 2014). Mult iple, proximally located SPs, as 
well as large sized (>1 cm) polyps have been reported to associate 
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with synchronous and subsequent SPs and CRCs, potent ially 
reflect ing the fast growth rate and high risk of malignant 
progression of these lesions (Álvarez et al. 2013, Hiraoka et al.  
2010, Lazarus et al. 2005, Schreiner et al. 2010).  
Recent ly, SSAs and HPs, regardless of their location, were reported 
to often be present in the periphery or stalk of TSAs or even as 
int imately admixed forms with a typical TSA component suggest ing 
the possibility that also HPs, generally considered as innocent  
lesions, may progress to TSA and further to CRC (Kim et al. 2013).  
 
1.2.4 Mixed Polyp 
The mixed polyp variant displays features of hyperplast ic polyp and 
SSA, and a dysplast ic component resembling convent ional adenoma. 
These polyps tend to occur in the right side of the colon, are smaller 
in size, and show a predominance of BRAF mutation with MSI -H 
and CIMP-H profile. They may represent a SSA evolving to 
cytological dysplasia and carcinoma because a mixed ser rated and 
adenomatous transit ion zone is commonly noted when SSA is found 
in conjunct ion with carcinoma (Harvey & Ruszkiewicz 2007).  
Table 1 indicates benign and premalignant epithelial tumors of the 
colon and rectum.  
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Classification  Designating features 
Traditional adenomas  Presence of dysplastic epithelium 
Tubular adenoma Tubular glands 
Villous adenoma Leaf- or fingerlike projections of the epithelium 
overlying lamina propria 
Tubulovillous adenoma 
(TVA) 
Mixture of tubular and villous components; villous 
component 25–75% 
Serrated polyps  Saw tooth-like infolding of the surface and crypt 
epithelium 
Hyperplastic polyp (HP) Serrations confined to the upper parts of the crypts, 
no cytological atypia 
Sessile serrated adenoma 
(SSA) 
Distortion of the normal crypt architecture: dilated 
and T- or L-shaped crypts, alterations in the position 
of proliferative zone; vesicular nuclei 
Traditional serrated 
adenoma (TSA) 
Ectopic crypt formation (ECF); cytological atypia 
Mixed polyps Display features of hyperplastic polyp and SSA, and 
a dysplastic component resembling conventional 
adenoma 
Table 1. Benign and premalignant epithelial tumors of the colon and rectum. 
Classification and designating features adapted from Hamilton et al. 2010, Mäkinen 2007, 
Torlakovic et al. 2008, Snover et al. 2010. 
 
 
 
1.3 Colorectal cancer epidemiology and classification  
1.3.1 Incidence 
The gastrointest inal tract is one of the most common sites of 
carcinogenesis as a consequence of its high number of mitotic events 
and exposure to carcinogens (Leedham et al. 2005). 
Colorectal cancer (CRC) is the third most common cause of cancer 
death in the world (Parkin 2001, Center et al. 2009, Hutfless & 
Kalloo 2013) with approximately 5% lifetime prevalence in the 
Western world (Siegel et a l.  2014). The incidence rate (ASRs) in 
North America and Europe is approximately 30–50/100.000 
(Schottenfeld & Winawer 1996).  
In Europe, CRC is one of the most commonly diagnosed cancers,  
with more than 450,000 new cases reported annually. Unfortunately ,  
it  remains the second leading cause of cancer deaths in the WHO 
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European region (12.0% of all cancer-related deaths) (Curado 2011). 
Almost half of the populat ion will develop at least one benign 
intest inal tumor during their lifet ime and there is a sharp increase in 
CRC incidence in people over 70 years of age (Siegel et al. 2014).  
The highest CRC incidence rates have been reported in the 
developed countries with a westernized lifestyle, while in 
developing countries, the incidence rates are lower (Center et  al.  
2009).  
 
1.3.2 Genes and signaling pathways altered in CRC 
Several genet ic changes are required for the init iat ion and 
progression of CRC and they involve several crit ical genes and 
important signaling pathways (Fearon 2011, The Cancer Genome 
Atlas Network 2012).  
 
1.3.2.1 Oncogenes and tumor suppressor genes  
Studies in the 1980s and 1990s revealed that important steps in the 
carcinogenesis include the act ivat ion of pro -tumorigenic oncogenes 
and inact ivat ion of ant i-tumorigenic tumor suppressor genes 
(Vogelstein et al. 1988, Kinzler & Vogelstein 1997, Herman et al.  
1999).  
Proto-oncogenes distributed throughout the human genome control 
cell proliferat ion, different iat ion, apoptosis and growth. They can 
transform into oncogenes, with an ability to promot e cancer growth, 
by point mutations, chromosomal translocat ions, or gene 
amplificat ions and all of these mechanisms result  in either a change 
in the structure of their protein product or an increase in their 
expression. The products of oncogenes include transcript ion factors, 
chromatin remodelers, growth factors, growth factor receptors, 
signal transducers, and apoptosis regulators (Croce 2008, Markowitz 
2009). 
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In contrast to oncogenes, the tumor suppressor genes inhibit  cell 
growth and different iat ion and thus suppress the neoplast ic 
progression (Fearon & Vogelstein 1990). Tradit ionally, the tumor 
suppressor genes have been suggested to act “recessively” at the 
cellular level, denot ing that both alleles must be inact ivated before 
the eliminat ion of growth-suppressive funct ion is lost (Knudson 
1971). However, subsequent studies have revealed in a proportion of 
tumor suppressor genes in CRC (e.g. tumor protein p53 (TP53) and 
deleted in colorectal carcinoma (DCC) that inact ivat ion of one gene 
copy may be sufficient in a dominant negative fashion (Fearon & 
Vogelstein 1990). However, most tumor suppressor genes are st ill 
considered to follow Knudson’s two-hit hypothesis of cancer 
development, according to which both gene copies need to be 
inact ivated for a phenotype (Knudson 1971).  
In cancers with hereditary background, the first hit is an inherited 
mutation of the tumor suppressor gene in a germline cell, whereas 
the second hit is restricted to the somatic cancer progenitor cell in 
target tissue. Conversely, in sporadic cancers, two inact ivat ing hits 
(one in each allele) occur somatically before the tumor init iat ion, 
and these hits can be either genet ic (e.g. mutations) or epigenet ic 
(e.g. promoter methylat ion) (Peltomäki 2014).  
The tumor suppressor genes can be c lassified into three different  
categories based on the funct ion of their gene products (Michor et 
al. 2004). In CRC the “gatekeepers” (genes with the ability to 
direct ly regulate tumor growth) are adenomatosis polyposis coli 
(APC) and TP53. The “caretakers” (genes that maintain genomic 
instability increasing mutat ions in other genes) are rappresented by 
MLH1 in CRC (Kinzler & Vogelstein 1997, Michor et al. 2004).  
The third class “landscapers” encode gene products that affect the 
cellular microenvironment: phosphatase and tensin homolog (PTEN) 
in CRC that, cause the distruption of the normal interact ions 
between cell and stromal environment (Michor et al. 2004). Table 2 
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shows a group of oncogenes and tumor suppressor genes commonly 
associated with CRC pathogenesis.  
 
Gene  Significance of the gene product 
Oncogenes  
KRAS  Activation of MAPK-ERK signal, transduction, inhibition of 
apoptosis, promotion of cell survival (Bos et al. 1987). 
BRAF  Activation of MAPK-ERK signal, transduction, inhibition of 
apoptosis, promotion of cell survival (Davies et al. 2002). 
β-catenin  Activation of Wnt signaling that regulates cell proliferation 
and invasion (Morin et al. 1997). 
Tumor suppressor genes  
APC  Inhibition of Wnt signaling via degrading β- catenin (Morin et 
al. 1997). 
TP53  Cell cycle regulation (Baker et al. 1990). 
TGFβR2  Receptor that is responsible for TGFβ pathway signaling 
mediating growth arrest and apoptosis (Markowitz et al. 
1995). 
SMAD2 and -4  Important component of TGFβ pathway signaling mediating 
growth arrest and apoptosis (Thiagalingam et al. 1996). 
MLH1, MSH2, and 
MLH6  
Enzymes contributing to DNA mismatch repair and 
maintaining the stability of DNA microsatellites (Fishel et al. 
1993, Herman et al. 1998, Miyaki et al. 1997, Papadopoulos 
et al. 1994, Strand et al. 1993). 
Table 2. Oncogenes and tumor suppressor genes commonly associated with CRC 
pathogenesis. Modified from Markowitz & Bertagnolli 2009. 
 
 
1.3.2.2 Signaling pathways altered in CRC 
The key signaling pathways, according to current understanding, 
including WNT (wingless), MAPK-ERK (mitogen-act ivated protein 
kinase extracellular signal-regulated kinase), PI3K 
(phosphat idylinositol 3-kinase), TGF-β (transforming growth factor-
β), P53 and DNA MMR (Markowitz 2009, The Cancer Genome Atlas 
Network 2012). Noteworthy, most CRCs show alterat ions in 
mult iple pathways (The Cancer Genome Atlas Network 2012).  
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Wnt signaling 
Wnt pathway is the most altered in CRC (>90%), most frequent ly by 
the biallelic inact ivat ion of APC (Markowitz 2009, The Cancer 
Genome Atlas Network 2012). APC is a tumor suppressor gene that 
regulates the phosphorylat ion of oncoprotein β-catenin/T-cell factor 
(TCF) dependent transcript ion and the degradat ion of β-catenin in 
proteasomes by ubiquit in ligases as a part of a protein complex 
modulated by the Wnt signaling pathway (Aoki & Taketo 2007). In 
CRC the inact ivat ion of APC causes the accumulat ion of β-catenin 
in the cytoplasm and nucleus, followed by const itutive,  
inappropriate act ivat ion of the Wnt signaling pathway and the 
altered expression of mult iple genes participat ing in cell 
proliferat ion, different iat ion, apoptosis, and migrat ion (Aoki & 
Taketo 2007). 
 
The mitogen-activated protein kinase extracellular signal-regulated 
kinase pathway 
The MAPK cascades are important pathways mediat ing the cellular 
response to extracellular signals that regulate normal cell growth, 
different iat ion and survival. The ERK pathway is the best known of 
these pathways (Dhillon et al. 2007) and the protein products of the 
proto-oncogenes KRAS and BRAF are the subsequent mediators in 
the MAPK-ERK pathway (Fearon 2011, The Cancer Genome Atlas 
Network 2012).  
The proto-oncogene KRAS is a member of the Ras family encoding 
a group of enzymes named GTPases (guanosine triphosphatases),  
which funct ion downstream of several different receptor tyrosine 
kinase (RTK) growth factor receptors, e.g. the EGFR family (Fearon 
2011, Wennerberg et al. 2005, Worthley & Leggett 2010). The 
protein product of KRAS is an important mediator in signal 
transduct ion pathways mediat ing the extracellular signals into 
intracellular signal cascades including the MAPK-ERK and the PI3K 
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pathways (Fearon 2011, Malumbres & Barbacid 2003, The Cancer 
Genome Atlas Network 2012). In approximately 40% of CRCs, 
KRAS is somatically mutated and the act ivat ing mutations  of RAS 
genes result  in a const itutive downstream signaling through the 
MAPK-ERK pathway, and further cont inuous cell growth (Fearon 
2011, Worthley & Leggett 2010). KRAS mutations are often already 
detected in early adenomas and even in ACFs (Fearon 2011, 
Rosenberg et al.  2007), as well as other cancers such as pancreat ic,  
lung and thyroid cancers (Dhillon et al. 2007). KRAS mutation is 
found in 30% of serrated adenomas and is more commonly 
associated with the tradit ional serrated adenoma subtype. The 
serrated pathway exhibits low levels of methylat ion and 
microsatellite instability (MSI-L).  
The BRAF protein, encoded by the proto-oncogene BRAF, belongs 
to a family of serine/threonine kinases (known as RAF kinases 
family) that were originally ident ified as retroviral oncogenes at the 
beginning of the 1980s (Rahman et al. 2013). BRAF is one of the 
direct downstream effectors of KRAS in the MAPK-ERK pathway 
(Dhillon et al. 2007). Phosphorylated by RAS, BRAF act ivates its 
downstream effectors MEK1 and MEK2, which subsequent ly 
phosphorylate ERK1 and ERK2. Act ivated ERK1/2 further transmits 
the signals to its downstream cytosolic and nuclear effectors 
regulat ing normal cell growth, different iat ion and survival (Dhillon 
et al. 2007, Rahman et al. 2013). Over 65 BRAF mutat ions have 
been discovered and most of these are found in exon 11 and 15 
(Rahman et al. 2013). The most frequent mutation type (>90% of 
oncogenic BRAF mutations) is a missense mutation in exon 15 (the 
valine to glutamic acid subst itution at the residue posit ion 600) 
known as BRAFV600E (formerly 599E) (Davies et al. 2002, Wan et al.  
2004).  
Furthermore, although these genes locate one after another in the 
MAPK-ERK pathway, the BRAF and KRAS mutated cancers possess 
dist inct clinicopathological characterist ics reflect ing the numerous 
downstream effector pathways of KRAS (Dhillon et al. 2007).  
41 
 
Stefanius et al demonstrated a high frequency of KRAS mutations 
(45.2%) in serrated adenocarcinoma, suggest ing that a significant 
proportion of KRAS mutated CRC originates from serrated polyps 
(Stefanius et al. 2011). Like KRAS mutations, also BRAF mutat ions 
are thought to occur in the early steps of the CRC tumorigenesis,  
based on the finding that mutations are already detected in small 
polyps and ACFs (Markowitz 2009). Furthermore, the mutation of 
BRAF is strongly associated with CIMP (cytosine-phosphoguanine 
island methylator phenotype), MSI (microsatellite instability)  and 
the serrated pathway of CRC (Fearon 2011, Markowitz 2009, 
Nagasaka et al. 2004, Stefanius et a l. 2011, Weisenberger et al.  
2006).  
 
NOTCH 
The Notch pathway is highly conserved, with homologs in species 
ranging from worms through Man (Andersson et al. 2011). The 
Notch signaling pathway in humans consists of four receptors, 
Notch-1, -2, -3, -4 and at  least five ligands, Jagged-1, Jagged-2, 
Delta-1, Delta-3 and Delta-4 (Mumm & Kopan 2000). In the 
canonical Notch pathway, ligand interact ion with receptor results in 
a cascade of proteolyt ic cleavages mediated first by a 
metalloprotease and second by a γ-secretase act ivity. These cleavage 
steps result in release of a const itutively act ive intracytoplasmic 
Notch (ICN) fragment that is then translocated to the nucleus, where 
it associates with CBF-1 and MAML-1 as part of a larger 
transcript ion complex (Kovall 2008). The net effect of ICN is to 
switch transcript ional complexes of CBF-1 from repression to 
act ivat ion (Lai 2002). Notch signaling is terminated by CDK8-
mediated phosphorylat ion of a PEST domain on the ICN. This then 
targets ICN for proteosomal degredat ion and allows the cells to be 
responsive to new Notch signals (Mumm & Kopan 2011, Andersson 
et al. 2011, Kovall 2008).  
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The role of Notch signaling in normal intest inal development has 
been well-documented and is the subject of several excellent 
reviews (Geissler & Zach 2012, Medema & Vermeulen 2011, 
Vaiopoulos et al. 2012, Fre et al. 2011, Vooijs et al. 2011, 
Miyamoto & Rosenberg 2011). In the colon, Notch signalling is 
involved in the control of stem cells and transit amplifying cell 
division (Fre et al. 2005, Van Es et al. 2005). Lateral inhibit ion in 
this cell-to-cell signaling pathway means that adjacent cells are 
driven towards different fates, result ing in a caotic distribut ion of 
progenitor cells committed to enterocyte and secretory lineages 
(Noah & Shroyer 2013).  
 
Transforming growth factor-β signaling  
The later genet ic step thought to be involved in a fract ion of CRCs 
is the inact ivat ion of the TGF-β signaling pathway (Lampropoulos et  
al. 2012, Markowitz 2009). TGF-β signaling cascades are normally 
involved in many cellular processes such as cell growth, 
different iat ion, apoptosis, and migrat ion, triggered by the binding of 
the TGF-β superfamily ligands (in carcinogenesis TGF-β1) to the 
type II receptor (TGFBR2; transforming growth factor, bet a receptor 
II) in the cell membrane. The binding to TGFBR2 recruits and 
phosphorylates a type I receptor (TGFBR1) which further 
phosphorylates receptor-regulated SMADs (mothers against 
decapentaplegic homolog), SMAD2 and SMAD3, and triggers a 
complex format ion with SMAD4, which then accumulates in the cell 
nucleus (where SMAD2 and SMAD3 can also enter in a SMAD4-
independent fashion). In the cell nucleus, SMADs act as 
transcript ion factors participat ing in the regulat ion of target gene 
expression, engaged in an ambiguous role as both tumor suppressor 
and cancer promoter, inducing among others, p21, a cyclin-
dependent kinase inhibitor, leading to growth arrest (Lampropoulos 
et al. 2012). 
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In CRC tumorigenesis, TGF-β and its signaling effectors have been 
reported to influence cancer biological behavior (disease 
progression, the degree of different iat ion of primary tumor, 
metastasis and recurrence), as well as to affect mult iple components 
of the human immune system, thus playing a role in carcinogenesis 
through immune suppression (Lampropoulos et al. 2012).  
The most common mechanism, result ing in the alterat ion of the 
TGF-β signaling pathway, is the mutat ion of TGFBR2, detected in 
about one third of all CRCs (Lampropoulos et al. 2012, Markowitz 
2009). In sporadic colon cancer,  loss of phosphorylat ion of SMAD1, 
SMAD5 and SMAD8 has been observed in 70% of cancers (Kodach 
et al. 2008). Contrary to SMAD4, SMAD2 mutat ion occurs more 
often in the early stages of tumor development and is specifically 
associated with sporadic cancers (Lampropoulos et al. 2012).  
 
Bone morphogenetic protein  
Bone morphogenet ic proteinS (BMPs), first ident ified for their role 
in controlling bone format ion, are members of the TGF β 
superfamily (Massagué 1998). BMPs bind to the BMP receptors I 
(BMPRI) or II (BMPRII). BMP binding to BMPRII results in 
phosphorylat ion of BMPRI, which subsequent ly phosphorylates 
SMAD1, SMAD5 and SMAD8. These then associate with SMAD4, 
result ing in act ivat ion and nuclear localization (Schmierer & Hill 
2007).  
BMP signalling has a pivotal role in intestinal development and is 
required for the control of intest inal stem cell replicat ion. It is also 
needed for terminal different iat ion of mature intest inal cells 
(Auclair et al. 2007). BMP ligands are secreted from both epithelial 
and mesenchymal cells but act mainly on the epithelial compartment 
through epithelial cell expression of BMP receptors (Hardwick et al.  
2004). BMP signaling is act ive in the different iated compartment, 
and despite the presence of BMP protein, it  is relat ively inact ive in 
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early compartments in the base of the crypt due to the presence o f 
the BMP inhibitor Noggin (Hardwick et al. 2008, Kosinski et al.  
2007).  
In colon cancer, mutations in SMAD4 or BMPRI have been shown to 
be responsible for juvenile polyposis (Hardwick et al. 2008). Loss of 
SMAD4 or loss or BMPRII is the likely mechanist ic basis for loss of 
BMP signaling in sporadic colon cancers. However, because studies 
have indicated that loss of BMP signaling in sporadic colon cancers 
correlates with tumor grade, it  is likely that this is not an init iat ing 
event (as it  is in juvenile polyposis), but rather contributes to tumor 
progression (Hardwick et al. 2008). There is increasing evidence in 
sporadic colon cancers (as compared with JP) that mutations 
affect ing BMP signaling corroborate with act ivated WNT to drive 
colon cancers, part icularly in later stages (Hardwick et al. 2008).  
 
Hedgehog 
The Hedgehog (HH) pathway derives its unusual name from the 
phenotype of hedgehog loss in Drosophila; larvae take on a curled, 
brist ly appearance that may remind some of a hedgehog (Geissler & 
Zach 2012). In humans, there are three HH proteins, Sonic HH, 
Indian HH and Desert HH.  
HH is synthesized as a 45 kDa precursor that is self-cleaved into C- 
and N-terminal pept ides. The role of the C-terminal pept ide is 
unknown, but the N terminal forms the act ive HH ligand (Taipale & 
Beachy 2001). HH can bind to its receptor, Patched, which then de -
represses the membrane-bound protein Smoothened (Smo). This 
cause the act ivat ion and release of Gli transcript ion factors that can 
translocate to the nucleus. Vertebrates have three Gli proteins. Gli1 
will result in act ivat ion of HH target genes,  while Gli3 is a repressor 
of signaling. Gli2 serves a dual role, with both repressive and 
act ivator funct ions (Geissler & Zach 2012).  
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Genes regulated by HH signaling include Myc, Bcl-2 and the Notch 
ligand, Jagged2. Also induced by HH signaling are the stem cell -
associated proteins LGR5, CD133 and CD44, as well as 
transcript ion factors that regulate epithelial to mesenchymal 
transit ion (EMT) such as Snail, Slug and Twist (Katoh & Katoh 
2006). 
Indian hedgehog is the main HH protein expressed in the intest ine 
and is secreted in a paracrine manner by different iated epithelial 
cells to act on mesenchymal cells. It maintains homeostasis of 
mesenchymal cells and regulates epithelial cell proliferat ion through 
negat ive feedback to proliferat ing crypt base columnar cells by 
increasing BMP signaling (Buller et al. 2012).  
Mutations that result in act ivat ion of HH signaling are the driver 
mutations in basal cell carcinomas, for which there are now targeted 
therapies (Weiss & Korn 2012). Evidence from mouse models 
indicates that HH may cooperate with activated WNT to drive 
lethality in colon cells (Varnat et al. 2010). This suggests that HH 
inhibitors may be an interest ing target to consider in colon cancer.  
HH has moved more to the forefront of a potent ial targeted therapy 
in cancer (Tang et al. 2012).  
 
P53 signaling 
Another key genet ic step in CRC tumorigenesis is the inact ivat ion of 
the P53 pathway as a result of the mutation of tumor suppressor 
gene TP53 (Fearon 2011, Markowitz 2009). This gene was already 
discovered in the late 1970s and has been reported to be mutated in 
about half of almost all cancers (Johnson et al. 1993).  
P53 protein is encoded by the TP53 gene. It is a key transcript ional 
regulator of genes responsible for the encoding of proteins that 
funct ion in the cell-cycle checkpoints, restrict angiogenesis and 
promote apoptosis.  
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In normal situat ion, wild-type P53 arrests or slows down the cell 
cycle in G1/S phase and addresses the DNA damage requiring repair 
to caretaker genes when mutat ions or replicat ion errors o ccur. 
Furthermore, when the damage is too extensive,  P53 may induce 
apoptosis (Johnson et al. 1993).  
In most of the somatic CRCs, both alleles of TP53 are inact ivated by 
a combinat ion of a missense mutation inact ivat ing the 
transcript ional act ivity and a chromosomal delet ion of a 17p 
eliminat ing the second TP53 allele; this occurs typically in the later 
phase of the tumorigenesis (often with the transit ion of large 
adenoma into carcinoma). However, in CRCs with MMR defects,  
TP53 often remains wild-type (Markowitz 2009). ATM (ataxia 
telangiectasia mutated), a kinase that phosphorylates and act ivates 
P53 after DNA damage, is another altered gene in the P53 pathway, 
which is found mutated in a trend toward mutual exclusivity with 
TP53 in CRC (The Cancer Genome Atlas Network 2012). 
 
1.3.2.3 Communication between pathways  
There is an increasing body of evidence from a variety of t issues 
that these developmental pathways exhibit  cross-talk or share 
molecular points (nodes) of intersect ion (Geissler & Zach 2012, Lin  
&Hankenson 2011). In addit ion to cross-talk, these various 
developmental pathways can also have an impact on cell signaling 
pathways such as PI3K/Akt and Ras/Raf/Mek/Erk (Ruizi 2011, Beck 
& Carethers 2007, Beck et al. 2007, Chappell et al. 2011).  
WNT signals can control Gli3 from the HH pathway (Alvarez-
Medina et al.  2008). HH can antagonize WNT signaling in the colon 
(Van den Brink et al. 2004, Watt 2004). Likewise, HH has been 
reported to control the expression of the Notch ligand Jagged2, 
whereas WNT/β-catenin can control Jagged1 (Estrach et al. 2006, 
Chen et al. 2010). Hes-1 can be act ivated by both Notch and HH 
signaling (Wall & Wallace 2009, Wall et al.  2009, Sang et al. 2010).  
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BMP and WNT appear to be interconnected via the PI3k/Akt 
pathway (Tian et al.  2005). TGF β/Smad signaling promotes EMT 
through WNT, Ras, HH and Notch (Fuxe et al. 2010). Thus, there is 
interplay between these pathways, and alterations in one could have 
potent ial effects on others. Other work has implicated interact ions 
between PTEN/PI3K/Akt signaling and BMP in colon cancers (Beck 
& Carethers 2007, Chen et al. 2011).  
Hedgehog and Ras have been reported to be interconnected in colon 
cancer (Mazumdar et al. 2011).  Connect ions between HH and p53 
have also been proposed, further i llustrating the complex 
interconnect ivity between signaling pathways (Ho & Alman 2010, 
Efstratiadis et al. 2007).  
 
1.3.2.4 Genomic instability  
The spontaneous mutation rate in somatic cells is not sufficient to 
account for the mutational load observed in many human tumors. 
The loss of genomic stability could explain this discrepancy and the 
rapid acquisit ion of new tumor-associated mutations needed for 
cancer development during a pat ient’s lifet ime (Loeb 1991).  
Subsequent studies confirmed the crucial role of genomic instabilit y 
for carcinogenesis, which may be acquired by three pathways: 
chromosomal instability (CIN), MSI, and CIMP (Markowitz 2009, 
Worthley & Leggett 2010). 
 
Chromosomal instability  
In CRC, chromosomal instability (CIN) is the most common type of 
genomic instabilit y (~70–85% of sporadic CRCs), which causes 
changes, either gains or losses, of whole or large portions of 
chromosomes (Bogaert & Prenen 2014, Markowitz 2009). As a result  
of unequal distribut ion of DNA, the daughter cells fail to ga in the 
same number or similarly structured chromosomes in the cell 
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division, leading to karyotypic variability from cell to cell. As a 
consequence of CIN, an imbalance in chromosome number 
(aneuploidy), chromosomal rearrangements, and frequent loss of 
heterozygosity (LOH), inact ivat ing the functioning allele of a tumor 
suppressor gene, are seen (Bogaert & Prenen 2014, Michor et al.  
2004). 
Whole-genome sequencing of CRC samples has revealed that the 
chromosome regions affected by arm-level changes include gains of 
1q, 7p and q, 8p and q, 12q, 13q, 19q, and 20p and q, and losses of 
18p and q (including SMAD4 in 66% of the tumors), 17p and q 
(including TP53 in 56% of tumors), 1p, 4q, 5q, 8p, 14q, 15q, 20p, 
and 22q (The Cancer Genome Atlas Network 2012). The kar yotypic 
abnormalit ies observed in CIN coupled with the specific mutat ions 
of oncogenes and tumor suppressor genes (e.g. APC, CTNNB1, 
KRAS, BRAF, PIK3CA, SMAD4, TP53) lead to the act ivat ion of the 
previously presented signaling pathways crit ical for CRC init iat ion 
and progression (Bogaert & Prenen 2014). The factors underlying 
CIN in CRC are poorly defined, but recent ly published studies have 
suggested that defects in genes regulat ing format ion of mitotic 
spindle and proper alignment and segregation of chromosomes at 
mitosis may be involved. The inact ivat ion of APC may also have 
some effect in CIN (Fearon 2011, Pino & Chung 2010). CRCs 
characterized by CIN have been reported to have poor prognosis 
regardless of tumor stage or therapy, and more commonly favor the 
distal colon (Kim & Kim 2014).  
 
Microsatellite instability  
Another important pathway for genomic instability is caused by the 
dysfunct ion of DNA MMR genes and is known as the MSI pathway 
(Mäkinen 2007). It was first described in Lynch syndrome (LS) 
patients (formerly known as hereditary non-polyposis colon cancer; 
HNPCC), with a germ-line mutat ion in MMR genes, at the beginning 
of the 1990s (Peltomäki 2005).  
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Microsatellites are repet it ive nucleot ide sequence motifs 1–6 base 
pairs in length within the genome that are prone to mismatch errors 
during the DNA replicat ion as a result of impaired MMR. If the 
errors are not corrected, the daughter DNA may gain a different  
number of sequence repeats within a microsatellite in each 
replicat ion cycle, result ing in MSI (Bogaert & Prenen 2014, 
Markowitz 2009). 
In sporadic CRCs, the inact ivat ion of MMR gene, typically MLH1, 
most ly occurs due to the biallelic silencing of the gene expression, 
as a result of promoter hypermethylation. This phenomenon 
represents an epigenet ic change in tumor development. De novo 
germline mutations or somatic mutations in MMR genes are 
infrequent in sporadic MSI-H cancers (Fearon 2011). Overall, MSI-
H can be detected in about 15% of all CRCs, while the germ-line 
mutation, represent ing the inherited background of CRC in the 
known MMR genes, is encountered in only ~3% of CRC pat ients 
(Fearon 2011, Markowitz 2009).  
Several clinicopathological features separate sporadic MSI -H CRCs 
from non-MSI tumors. In sporadic setting, MSI is often associat ed 
with BRAF mutat ion and high-level CIMP (CIMP-H) and 
accompanied by histology of serrated pathway neoplasms (Mäkinen 
2014, Stefanius et al. 2011). These tumors also typically locate in 
the proximal colon and they tend to occur in elderly women 
(Mäkinen 2007, Poynter et al. 2008).  
In both inherited and sporadic background of MSI-H CRCs, typical 
histological features include poor differentiat ion with mucinous or 
signet ring cell appearance, tumor-infilt rating lymphocytes and 
peritumoral Crohn-like infiltrate (Boland & Goel 2010).  
While the MSI-H tumors seem to form a dist inct clinicopathological 
phenotype, the concept of MSI-L in CRC is controversial (Pawlik et 
al. 2004). The biological basis of the MSI-L phenotype is uncertain,  
as no alterations in MMR genes MLH1, MSH2, MSH6, or PMS2 
have been reliably associated with this phenotype. Conversely, the 
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methylat ion of the DNA repair gene MGMT has been found to be the 
most frequent in a fract ion of sporadic CRCs with MSI -L and to be 
associated with the serrated pathway adenomas and SACs. Thus, it  
has been suggested that an increased production of DNA mismatches 
due to the loss of expression of MGMT could stress the DNA MMR 
system and thus lead to the MSI-L phenotype (Jass 2007, Mäkinen 
2007). 
 
Epigenetic alterations 
Epigenet ic alterat ions modify the transcriptional potential of a gene 
without changes in the DNA sequence (Bonasio et al. 2010). DNA 
methylat ion is the best -known epigenetic phenomenon and is 
current ly considered the most important in CRC pathogenesis 
(Esteller 2008).  
In sporadic CRC, both loss of global DNA methylat ion (i.e., 
hypomethylat ion) and an increase of methylat ion in the promoter 
areas of selected CpG islands (i.e., hypermethylat ion) are present  
(Fearon 2011, Issa 2004). CIMP was introduced as a pathway o f 
CRC tumorigenesis in 1999 (Toyota et al. 1999). During evolut ion, 
most of the CpG dinucleotides (short areas of cytosine nucleot ide 
followed by a guanine nucleotide) were lost in the genome. 
However, approximately 50% of all genes st ill cont ain these 
dinucleotides (i.e., CpG islands) as dense clusters in their promoter 
areas (Fearon 2011). The aberrant addit ion of methyl groups (CH 3) 
to CpG sites in the promoter region has been associated with 
inappropriate transcript ional silencing of the genes regulated by 
these promoters. Deregulat ion of gene expression of certain key 
tumor suppressor genes has been reported to enhance tumorigenesis 
in several other tumor types besides CRC, such as gastric, liver,  
pancreat ic, endometrial, ovarian, breast and lung cancers (Esteller 
2008, Issa 2004). 
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In sporadic CRCs, the hypermethylat ion of tumor suppressor gene 
MLH1 is the major cause of MSI and an important pathway to 
genomic instability (Leggett & Whitehall 2010). Approximately a 
third of all CRCs and near ly all MSI-H tumors harbor CIMP. 
However, conversely, CIMP is not limited to this tumor type, 
whereas approximately half of all CIMP tumors do not carry MLH1 
methylat ion or MSI (Leggett & Whitehall 2010). CIMP can already 
be detected in SPs, especially in proximal SSAs (Leggett & 
Whitehall 2010).  
CRCs characterized by CIMP have been reported to differ by 
clinicopathological characterist ics (i.e., by age, sex and locat ion 
predilect ion, histology and prognosis) from non-CIMP tumors (e.g. 
CRCs deriving by tradit ional adenoma-carcinoma pathway).  
Typically, they tend to be proximal tumors in older individuals that 
show mucinous histology, thus sharing many features with MSI 
tumors (Leggett & Whitehall 2010).  
Furthermore, CIMP tumors have been associated with poo r 
prognosis compared with non-CIMP tumors, especially when MSS 
(Barault et al. 2008, Dahlin et al. 2010, Issa 2004) and they have 
been reported to have an independent predict ive effect on response 
to chemotherapy treatment (i.e., 5-fluorouracil (5-FU)) (Iacopetta et 
al. 2008, Jover et al. 2011, Rijnsoever et al. 2003).  
 
1.3.3 Pathways to colorectal cancer  
CRC is defined by the invasion of tumor cells through muscularis 
mucosae to submucosa (Hamilton et al. 2010). The majority of CRC 
is sporadic. The differences in the incidence between countries 
around the world (Siegel et al.  2013) as well as immigrant studies 
(Dunn 1975, Kune et al. 1986, Shimizu et al. 1987) suggest that 
environmental factors contribute to the development of CRC 
(Bradbury et al. 2014, Koushik et al. 2007, Larsson & Wolk 2006, 
Schwingshackl & Hoffmann 2014).  
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Molecular and morphological developmental pathways have been 
described to understand the heterogeneity and complexity of CRC 
development from normal colonic epithelium to adenoma, and 
further, to adenocarcinoma. Three main pathways based on the 
developmental events during their progression can be recognized: 
inherited, sporadic and IBD-associated pathways (Beaugerie & 
Itzkowitz 2015, Fearon 2011).  
 
1.3.3.1 Inherited pathways 
10%–50% of all CRC are hereditary or familial clustering in 
etiology and they consist of rare condit ions known to predispose to 
development of cancer (Tops et al. 2009). Early-onset diagnosis and 
mult iple affected relat ives (either with CRC or with adenomas 
particularly under 50 years of age) are closely related to the 
increased risk of CRC. Furthermore, it  seems that the familial risk 
of CRC is greater if relat ives have colon rather than rectal cancers,  
supporting the suggest ion of a slight ly different etiological basis 
behind these two diseases (Johns & Houlston 2001).  
The most common CRC syndrome, Lynch syndrome (LS) is 
responsible for 1–3% of all CRC cases (Lynch & de la Chapelle 
2003). Another well-described inherited syndrome, familial 
adenomatous polyposis (FAP), accounts approximately 1% of all 
CRCs, followed by recent ly defined MUTYH or MYH (mutY 
homolog) gene associated polyposis (MAP) (~1%), serrated 
polyposis syndrome (SPS), hereditary mixed polyposis syndrome 
(HMPS), and rare hamartomatous polyposis syndro me (Tops et al.  
2009, van Herwaarden et al. 2015).  
 
1.3.3.2 Sporadic pathways 
The vast majority of CRCs (50%–90% of all CRCs) arise in pat ients 
without a family history of CRC and these cancers are termed 
53 
 
“sporadic”. As a difference from inherited cancers,  a germline 
mutation as an init iat ing event is absent and the development of 
CRC is presumed to occur as a result of somatic changes, which are 
per se more suscept ible for environmental factors (Markowitz 2009).  
Earlier, the vast majority of CRCs were presumed to develop 
through a relat ively linear sequence of steps known as the 
Vogelstein adenoma-carcinoma sequence: the suppressor pathway 
characterized by CIN and init iated with a mutation of the APC 
tumor suppressor gene (Fearon & Vogelstein 1990, Muto et  al.  
1975). Later, the discovery of the SPs and the subsequent studies 
confirming their status as the precursor lesions of a subset of CRCs 
led to the introduction of a dist inct, alternat ive developmental 
pathway current ly known as the serrated pathway (Ja ss et al. 2002).  
Based on molecular studies, it  is est imated that approximately 80% 
of the CRCs develop along the convent ional pathway, which st ill 
serves a relevant model for the most common form of sporadic CRC 
(Jass 2007), whereas up to 20% of all CRCs arise along the serrated 
pathway (Mäkinen 2014, Snover 2011).  
 
The classical adenoma-carcinoma sequence 
Approximately 70-80% of sporadic CRC arise from the 
‘convent ional’ adenoma-carcinoma pathway. In the classical genet ic 
model for colorectal tumorigenesis described by Fearon and 
Vogelstein the evolut ion of colorectal cancer follows the adenoma-
adenocarcinoma sequence which is driven by the progressive  
accumulat ion of a number of crit ical mutat ions (Fearon & 
Vogelstein 1990).  
The pathogenesis of this pathway has been well studied and is 
centered around the accumulat ion of genet ic (Parkin 2001, Grady et 
al. 2005, Lewis et al. 1999) events in the luminal epithelial cells and 
is classically associated with the gradual development of CIN.  
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In this pathway, CRC starts by hyperproliferat ion in the normal 
epithelium and aberrant crypt ic foci forming small adenoma. Thus 
the genet ic inact ivat ion of the adenomatous polyposis coli (APC) 
gene causes the development of adenomatous polyps, the principal 
precursor of co lorectal cancer (Fearon & Vogelstein 1990, Pino & 
Chung 2010). The inact ivat ion of the APC occurs in up to 85% of 
sporadic CRCs and represents an early and crit ical, possibly rate -
limit ing, event in the tumorigenesis of most MSS CRCs, found 
already in microscopic adenomas (Fearon 2011, Markowitz 2009, 
Powell et al.  1992).  This is followed by the stepwise accumulat ion 
of other genet ic mutations, such as the KRAS that will increase the 
size into large polyp and with the combinat ion of TP53 genes 
mutation and the loss of heterozygosity (LOH) at chromosome 18q, 
malignant cells will appear forming the colon carcinoma (Fearon & 
Vogelstein 1990) (Figure 3).  
While the inact ivat ing mutation of APC is presumed to be the 
init iat ing step of the tumorigenesis, mutations of KRAS and TP53 
and LOH at chromosome 18q are required for the progression to 
larger adenomas and early carcinomas (Fearon & Vogelstein 1990, 
Pino & Chung 2010). The oncogenic mutation of KRAS most ly 
occurs in early adenomas (Fearon & Vogelstein 1990) and 
contributes to the transduct ion of signaling pathways such as 
MAPK-ERK and PI3K, as previously presented. 
The loss of chromosome 18q has been detected in up to 70% of 
sporadic CRCs (Pino & Chung 2010). Tumor suppressor genes 
SMAD2 and SMAD4 locate in this chromosome region and are thus 
mutated in a proportion of CRCs with 18qLOH, contribut ing to the 
act ivat ion of the TGF-β signaling pathway (Fearon & Vogelstein 
1990).  
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Figure 3. CRC development. From Sandouk et al. 2013. 
 
After forming carcinoma, there are five stages for the disease 
(Figure 4): stage 0 where the tumor locates in the mucosal layer of 
colon, stage I when it reaches the muscularis layer, stage II when it  
just perforates the serosa, stage III when the surrounding lymph 
nodes are involved, and last ly stage IV with distal metastasis 
(Sandouk et al. 2013).  
 
 
Figure 4. Stages of CRC . From Sandouk et al. 2013. 
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The serrated pathway 
Approximately 20% of the sporadic CRCs arise from the SPs via the 
serrated neoplasia pathway.  
Unt il the past two decades, almost all colorectal polyps were divided 
into hyperplast ic (serrated polyps), adenomas (TA, TVA, VA) and 
mixed polyps. Evidence that adenomas might not represent the only 
colorectal cancer precursor began to emerge around 1990 when a 
new category of serrated polyps, biologically different from 
hyperplast ic polyps, were recognized: tradit ional serrated adenoma 
(TSA), sessile serrated adenoma (SSA) and mixed polyp, all of 
which have malignant potent ial without the villous architecture of 
classic adenoma. The three variants of serrated adenomas have 
subt le architectural differences, but a ll have carcinogenic potent ial 
(Longacre & Fenoglio-Preiser 1990). 
In contrast with the adenocarcinoma sequence occurring through 
chromosomal instability, responsible for progressive accumulat ion 
of mutations in oncogenes and tumour-suppressor genes, the serrated 
neoplast ic pathway is characterized by aberrant methylat ion in 
promoter regions of specific genes based on hyper -methylat ion of 
CpGislands result ing in the “CpG islands methylator phenotype” 
(CIMP) at either low or high degree which reduces gene expression 
without altering the DNA sequence. Hyper-methylat ion may occur in 
DNA mismatch repair gene (MMR) hMLH-1 associated with the 
development of microsatellite unstable (MSI) cancer. MSI cancers 
occurring in the course of the serrated pathway are due to a loss of 
funct ion within DNA MMR system by promoter hyper -methylat ion 
of hMLH-1 only.  
The mutations of BRAF or KRAS, considered mutually exclusive,  
are the earliest events of the serrated route (Bettington et al. 2013, 
Mäkinen 2014). The mutual exclusivity supports the idea of the two 
individually branched serrated pathways of CRC. While the pathway 
involving BRAF is well characterized, the role of KRAS in serrat ed 
neoplasia is more controversial (Bettington et al. 2013, Mäkinen 
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2014). Also DNA hypermethylat ion occurs early (i.e., in ACF and 
even in the normal proximal colon mucosa in pat ients with SPS) but 
is generally more frequent in proximal polyps than in dis tal ones.  
The consequences of the hypermethylat ion are conformable with the 
target genes involved (e.g. the promoter methylat ion of MLH1 and 
MGMT leading to MSI-H and MSI-L, respect ively) (Mäkinen 2007, 
2014). 
Several other genet ic changes, such as loss of p16 due to the 
promoter methylat ion of CDKN2A (Dong et al. 2005, Kriegl et al.  
2011), TP53 mutation (Bond et al. 2012, Gaiser et al. 2013), APC 
mutation (Jass et al. 2006), somatic mutations of mitochondrial 
DNA in TSAs (Shimomura et al. 2011) as well as PTPRK-RSPO3 
fusions and RNF43 mutations (Sekine et al. 2016) and allelic 
imbalance of 18q (Yashiro et al. 2005) have been observed in the 
serrated pathway lesions, although as yet without adequately 
characterized significance. Furthermore, gene expression profile 
studies have revealed several different ly expressed genes between 
SACs and CCs, but many of these have not yet been studied on 
protein level (Conesa-Zamora et al. 2013, Laiho et al. 2007).  
 
1.3.4. Serrated colorectal cancer  
Serrated adenocarcinoma (SAC) is a dist inct variant of CRC, arising 
from the serrated precursor lesions via the previously described 
serrated pathway and represent ing approximately 20% of CRCs 
(Bettington et al. 2013, Mäkinen 2014).  The clinicopathological 
features commonly associated with SAC include female gender 
(Lash et al.  2010) and proximal tumor location (García-Solano et al.  
2010, Tuppurainen et al. 2005).  
The median age at the time of diagnosis of SAC does not differ 
notably from that of CCs (García-Solano et  al.  2010, Mäkinen et al.  
2001), but a rapid tumor progression along the serrated pathway is 
supported by several case reports of serrated precursor lesions 
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developing into a carcinoma (Mäkinen et al. 2002, Oono et al. 2009, 
Takeyoshi et al. 2002), as well as the studies reporting early SACs 
arising from small SSAs (Fujita et al.  2011, Goldstein 2006, 
Sheridan et al. 2006).  
 
1.3.4.1 The molecular classification of serrated colorectal cancer  
In 2007, Jass proposed a 5-t iered classification of CRC to clarify the 
origin and clinicopathological features of CRCs with different  
molecular backgrounds (Jass 2007). The classificat ion is st ill widely 
used, providing a helpful tool for researchers to compare the 
different subtypes of CRC.  
The serrated pathway carcinomas belong to  three broad molecular 
profiles: 1. BRAF mutant/CIMP-H/MSI-H, 2. BRAF mutant/CIMP-
H/MSI-L or MSS, and 3. KRAS mutant/CIMP-L/MSI-L or MSS. The 
first two groups are the most strongly associated with the serrated 
pathway and thus represent cancers most likely arising from SSAs. 
They also generally show CIMP-H regardless of the CIMP panel 
used. The last group of the serrated pathway CRCs are thought to 
develop from TSAs or even CAs and thus conversely to be less 
strongly associated with the serrated pathway (Bettington et al.  
2013, Jass 2007). Furthermore, two more subgroups: 4. CIN/CIMP-
neg./MSS (or MSI-L) and 5. LS/CIMP-neg./MSI-H rapresent CRCs 
arising from CAs, and complete the classificat ion (Jass 2007).  
Although the preceding subtypes roughly divide CRCs 
morphologically into SACs and CCs, the recognit ion of each subtype 
is often impossible based on the morphological features alone and 
thus, the molecular basis is principal for the classificat ion. The 
advantage of the classificat ion is the understanding of t he 
heterogeneity of the molecular background of CRCs and the 
possibility to consider each molecular type of cancer as an 
individual disease, harboring its own clinical,  histological, and 
prognostic features (Jass 2007).  
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1.3.5 Malignant neoplasms in colorectum 
Adenocarcinomas, with CRCs account ing for more than 90%, are the 
most common cancers in the colorectum (Hamilton et al.  2010, Kang 
et al. 2007). The great majority of adenocarcinomas are moderately 
different iated, showing a less resemblance to well-different iated 
adenoma-like epithelium with tubular structures (Treanor & Quirke 
2007).  
In addit ion to two most commonly encountered adenocarcinomas, 
convent ional colorectal carcinomas (CCs) and serrated 
adenocarcinomas (SACs), several somewhat overlapping 
histopathological variants can be microscopically dist inguished 
(Hamilton et al. 2010) (Table 3).  
 
 
Table 3. Histopathological subtypes of colorectal carcinoma. Classification and designating 
features adapted from Hamilton et al. 2010. 
 
  
Classification Designating features 
Adenocarcinoma, not otherwise 
specified 
Glandular differentiation 
Mucinous adenocarcinoma > 50% of the lesion is composed of 
extracellular mucin  
Signet-ring cell carcinoma Presence of > 50% of tumor cells with 
prominent intracytoplasmic mucin 
Serrated adenocarcinoma Epithelial serrations, low nucleus-to-cytoplasm 
ratio, clear or eosinophilic cytoplasm 
Micropapillary adenocarcinoma Tumor cells growing in papillary structures, 
which lack fibrovascular cores  
Medullary carcinoma Sheets of malignant cells with vesicular nuclei, 
prominent nucleoli,and abundant eosinophilic 
cytoplasm; prominent infiltration by 
intraepithelial lymphocytes 
Adenosquamous carcinoma Areas of glandular and squamous 
differentiation 
Undifferentiated carcinoma Lack of morphological, immunohistochemical, 
and molecular biology evidence of 
differentiation beyond that of an epithelial 
tumor  
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1.3.6 Molecular basis and sub-classification of CRC  
Recent molecular classificat ion of established tumors based on gene 
expression and (epi)genet ic mutation burden, has revealed 
considerable disease heterogeneity. Four dist inct CRC molecular 
subtypes (CMS) have been ident ified, each with a unique pathogenic 
molecular pathway, response to treatment and prognosis 
(Dienstmann et. al. 2014).  
Established tumor molecular classificat ion subtypes can be part ially 
reconciled with known precursor lesion subtypes. Canonical (CMS2) 
tumors are driven by disrupt ion of epithelial Wnt signaling through 
accumulat ion of genet ic mutations and chromosomal instability and 
arise from tubular and tubulovillous adenomas (convent ional 
adenoma-carcinoma sequence). Poor prognosis mesenchymal 
(CMS4) molecular signatures are defined predominant ly by stromal 
invasion and angiogenesis and prominent TGFβ act ivat ion (Calon et 
al. 2015, Isella et al. 2015). This subtype has the worst prognosis.  
These tumors are thought to arise through the serrated neoplasia 
pathway (De Sousa et al. 2013).  
 
1.3.7 Invasion and metastasis  
CRC is defined by the invasion of tumor cells through muscularis 
mucosae to submucosa although this has more to do with pract ical 
issues rather than dist inguishing between different biological 
ent it ies (Hamilton et al. 2010).  
The patterns of tumor cell invasion can be  classified into individual-
cell migrat ion, mult icellular migrat ion and expansive growth 
without migrat ion, which can be further divided into subcategories 
(Lauffenburger & Horwitz 1996, Ridley et al. 2003). The migrat ion 
mechanisms of an individual cell are similar to those occurring in 
normal non-neoplast ic cells in physiological condit ions, including 
cell polarizat ion and protrusion, adhesion format ion, act inand 
myosin-based contraction and rear detachment (Lauffenburger & 
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Horwitz 1996, Ridley et al. 2003). Different patterns of invasion are 
guided by the expression of cell-matrix adhesion molecules (e.g., 
integrins), cell-cell adhesion molecules (e.g., cadherins), matrix-
degrading enzymes (e.g., MMPs) and cell-cell communicat ion 
molecules (e.g., chemokines) (Friedl et al. 2012).  
Each tumor frequent ly presents with mult iple patterns of invasion 
(Friedl et al. 2012). About one in four CRCs shows infiltrat ive 
tumor border configurat ion, characterized by finger -like protrusions 
of the invasive front and represent ing collect ive cell migrat ion as 
strands, while the rest show a rather expansive tumor border 
configurat ion (Jass et al. 1996). At high magnificat ion, tumor buds,  
defined as isolated tumor cells or clusters of two to four cells at the 
invasive margin of the tumor, can be observed in the majority of 
CRCs (Hase et al.1993, Ueno et al. 2002) and cytoplasmic 
pseudofragments, i.e., dendrit ic processes of the budding cells, are 
present in half of the pat ients with highgrade budding, (Shinto et al.  
2005). Tumor budding is considered to represent weakening of cell-
cell adhesions and it often includes individual cell migrat ion 
(Natalwala et al. 2008). Accordingly, it  has been associated with 
decreased expression of the cell adhesion molecule E-cadherin 
(Zlobec et al. 2007).  
CRC commonly uses lymphat ic vessels (Minsky et al. 1989) and 
blood vessels (Krasna et al. 1988) as routes of metastasis.  The 
epithelial to mesenchymal transit ion (EMT) and single cell 
migrat ion may enhance the efficacy of metastasis (Christ ia nsen & 
Rajasekaran 2006). However, clusters of circulat ing tumor cells can 
be observed in CRC (Molnar et al. 2001) and other carcinomas 
including lung cancer (Hou et al. 2011), suggest ing that collect ive 
vascular invasion may also take place. The phenotype  of circulat ing 
tumor cells may influence the site of metastasis, as proposed by a 
human colon cancer xenograft mouse model that reported CD110+ 
cells being more likely to form liver metastases and CUB domain -
containing protein 1 expressing cells being more likely to form lung 
metastases (Gao et al. 2013).  
62 
 
1.3.8 Intratumoral hetereogeneity  
Intratumor heterogeneity is a phenomenon characterized by regions 
and cells with diverse genet ic and epigenetic changes, morphology, 
and behavior within a single tumor and its metastases (Almendro et 
al. 2013). CRC has been shown to present with heterogeneity within 
the primary tumors and between primary tumors and metastases in,  
e.g., activat ing mutat ions of KRAS (Baldus et al. 2010). Intratumor 
heterogeneity may represent a challenge for personalized medicine 
and biomarker development.Accumulat ing evidence suggests that 
not all tumor cells possess equal ability to proliferate.  
 
1.3.9 Colorectal cancer screening and treatment  
Colorectal cancer is an ideal disease for populat ion screening as it  is 
common, there is an effect ive surveillance tool (endoscopy), a well 
recognised premalignant precursor lesion (the colorectal polyp) and 
treatment of the premalignant condit ion reduces the risk of cancer 
(Leslie et al. 2002).  
The aim of the CRC screening is to ident ify the early stages of 
cancers which might still be treated with a curative intent and thus 
have a favorable prognosis (Jellema et al. 2010). The colonoscopy 
has been validated as the gold standard procedure for both ear ly 
detection and prevent ion of CRC as it allows the inspect ion of the 
ent ire colonic mucosa. It also allows resect ing pre-neoplast ic 
lesions, which reduces the incidence of colorectal cancer and thus 
the rate of deaths result ing from it (Zauber et al. 2012).  
However, at the t ime of diagnosis, approximately 15–25% of the 
CRC pat ients have metastases outside the bowel, most typically in 
the liver  and another 35–45% of pat ients will later develop 
metastases (Poston et al.  2005). Surgery is the primary modalit y o f 
treatment for CRC, and resect ion is the only therapy required for 
early-stage CRC (Nelson et al.  2001). While most of the pat ients 
(approximately 80%) with metastat ic disease are unresectable,  
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approximately 2–5% of all CRC pat ients have one or a few 
coincident metastases in one organ, staged as having oligometastatic 
disease potent ially treatable in a curat ive fashion (Van De Velde et 
al. 2014).  
The development of more effect ive chemotherapeut ic agents capable 
of inducing substant ial tumor shrinkage have enabled a significant  
proportion of pat ients who were init ially thought to be unresectable 
for cure to undergo metastectomy (Kanas et al. 2012).  
 
1.4 The tumor microenvironment 
In cancer research the cancer cell it self is most frequent ly the object 
of interest. The majority of human cancers are carcinomas that, by 
definit ion, arise from epithelial cells that line glands, ducts, and 
surfaces of organs (Landis et al. 1998). Consequent ly, the focus of 
research to date has been on epithelial cells, or more specifically 
genet ic changes that occur in epithelial cells as they progress from 
normal to malignant. Mult iple genet ic alterations are necessary for 
this transformation to occur (Foulds 1969). It has become clear that  
a cancer not only consists of neoplast ic cells but also contains a 
stromal infrastructure, including tumor vasculature, which is 
provided by the host. In fact, a neoplasm const itutes a unique 
microenvironment in which various subpopulat ions of tumor cells 
and tumor stroma interact and together determine the behavior of the 
neoplasm. A fascinat ing aspect of the stromal compartment of a 
tumor is that it  appears to be not only a passive scaffold or an inert 
supply system for cellular nutrients but an act ive regulatory 
element. It is in a way responsible for the existence of the tumor: 
without host stroma there would be no cancer (Bosma et al. 1993).  
Over 100 years ago, Paget et al. already proposed the importance of 
the tumor microenvironment with the theory of “seed & soil” (Paget  
1989). It has become increasingly apparent  that the stroma plays an 
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important role in promoting tumour progression (Coussens & Werb 
2002, Liotta & Kohn 2001, De Wever et al. 2008).  
 
1.4.1 Characteristics of tumor microenvironment  
The tumor microenvironment is composed by both cellular and non-
cellular components. The major cellular components include 
fibroblasts, endothelial and immune cells that, collect ively, produce 
the variety of molecules that represent the non-cellular components 
of the tumor stroma: i.e. the extracellular matrix (ECM) proteins, 
proteases, cytokines and growth factors (Hanahan & Weinberg 2000, 
Matrisian et al. 2001). All these components are funct ionally 
organized to promote survival of cancer cells in the host and 
generate a favorable microenvironment for cancer cells in both 
primary and metastat ic sites (Liotta & Kohn 2001).  
Moreover, tumor stroma format ion shares many important properties 
with wound healing, but wound healing is usually self-limited while 
the growth of tumors and tumor stroma is not. In fact, tumor stroma 
has been compared to a ‘wound that does not heal’ (Dvorak 1986, 
Eyden 2008).  
The molecular features of cancer stroma are less well understood 
than those of cancer cells, thus, in order to control and eradicate 
cancer, it  is very important to take in considerat ion not only 
malignant cancer cells, but also the benign stromal cells.  
 
1.4.2 Fibroblasts  
Fibroblasts were first described in the late 19th century, based on 
their locat ion and their microscopic appearance (Virchow 1858, 
Duvall 1879). They play a crit ical role in maintaining homeostasis 
in the microenvironment and in coordinat ing the complex 
physiological response to wounds (Mart in 1997, Iyer et al. 1999).  
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Fibroblats are embedded within the fibrillar matrix of the connect ive 
tissue and are, to a large extent, responsible for its synthesis. The 
important funct ions of fibroblasts include the deposit ion o f 
extracellular matrix (ECM), regulat ion of epithelial different iat ion , 
regulat ion of inflammation and involvement in wound healing 
(Tomasek et al. 2002, Parsonage et al. 2005). They also contribute 
to the format ion of basement membranes by secret ing type IV 
collagen and laminin (Chang et al. 2002). Fibroblasts are also an 
important source of ECM-degrading proteases such as mat rix 
metalloproteinases (MMPs), which highlights their crucial role in 
maintaining an ECM homeostasis by regulat ing ECM turnover 
(Chang et al. 2002, Simian et al. 2001).  
In addit ion, fibroblasts are important in maintaining the homeostasis 
of adjacent epithelia through the secret ion of growth factors and 
direct mesenchymal–epithelial cell interactions (Wiseman & Werb 
2002). Act ivated fibroblasts also have an important role as 
modulators of the immune response following t issue injury, through 
the secret ion o f cytokines such as interleukin-1 and chemokines 
such as monocyte chemotact ic protein 1 (MCP1) (Strieter et al.  
1989, Rollins et al. 1989). 
 
Heterogeneity and origins of CAFs 
Fibroblasts of the tumor stroma are called act ivated fibroblasts,  
peri-tumoral fibroblasts, myofibroblasts, tumor-associated 
fibroblasts or CAFs. They are the main cellular const ituents of 
stroma associated with primary and metastatic CRC (Herrera et al.  
2013, Mueller et al. 2007). Fibroblasts in cancer t issues are similar 
in morphology to myofibroblasts, which are large spindle-shaped 
cells that are act ivated during the wound healing process (De Wever 
et al. 2008). During the wound healing process, fibroblasts became 
“act ivated fibroblasts”, express α-smooth-muscle act in, leading to 
the term ‘myofibroblasts’(Kalluri & Zeisberg 2006) and ac t ively 
close the wound by contraction (Garana et al. 1992). During wound 
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healing, when the process is completed, activated fibroblasts 
decrease (Tomasek et al. 2002). In contrast, CAFs are perpetually 
act ivated and neither revert to a normal phenotype nor undergoes 
apoptosis and eliminat ion like normal fibroblasts (Li et al. 2007).  
The cont inued presence of myofibroblasts within a wound may be 
associated with fibrous neoplasms called fibromatoses (Fletcher 
2000), fibrotic disease (Desmouliere et al. 2005) a nd a 
predisposit ion to cancer (Chang et al. 2004). In addit ion, epithelia l 
tumors of a number of organs, including breast, are often surrounded 
by an act ivated stroma characterized by myofibroblasts that can 
promote tumorigenesis (Van den Hooff 1988, Olumi et al.  1999, 
Tlsty 2001, Tlsty & Hein 2001, Bissell et al. 2002, Coussens & 
Werb 2002, Beacham & Cukierman 2005, Orimo et al. 2005).  
It is becoming evident that CAFs origin can vary both between 
different tumor hystotypes and within different areas of ind ividual 
tumors. It is possible that CAFs are derived from several cell types 
and are therefore heterogenous (Sugimoto et al.  2006). There are 
several theories regarding the origins of CAFs, and this topic is st ill 
under debate. They can roughly classify the line of evidence about 
CAFs origin in: i) resident; ii)  mesenchymal stem cell (MSC) -
derived; iii) mutat ional (Cirri & Chiarugi 2011). For example,  
resident tissue fibroblasts, bone marrow-derived mesenchymal stem 
cells, hematopoiet ic stem cells, epithelial cells (epithelial-
mesenchymal transit ion; EMT) and endothelial cells (endothelial-
mesenchymal transit ion; EndMT) are all considered possible 
predecessors of CAFs. The transdifferent iation of CAFs, a process 
commonly called mesenchymal-mesenchymal transit ion (MMT) 
(Kalluri & Zeisberg 2006), is current ly poorly understood. TGF-β1 
has been largely acknowledged to be one of the major tumor -cell 
derived factors affect ing CAF act ivat ion (Lohr et al. 2001).  
 
 
 
67 
 
Tumor-Promoting Characteristics of CAFs 
Fibroblats contribute to tumor proliferat ion, invasion, and metastasis 
via secret ion of various growth factors, cytokines, chemokines, and 
degradat ion of extracellular matrix (ECM) proteins (Yamamura et  
al. 2015). Colon CAFs secrete epidermal growth factor (EGF), 
hepatocyte growth factor (HGF), IGF1/2, PGE-2, PDGF, fibroblast 
growth factor (FGF)-1 and vascular endothelial growth factor 
(VEGF) (Nakagawa et al. 2004, Peddareddigari et al. 2010, De 
Boeck et al. 2013, Torres et al. 2013). These growth factors act 
through act ivat ion of the mitogen-act ivated protein kinase (MAPK) 
and phosphat idylinositol 3-kinase (PI3K)/AKT pathways, which 
mediate cell proliferat ion and cell survival (ant i-apoptotic 
signaling), protein synthesis, cytoskeletal rearrangements, and 
invasion (Valenciano et al. 2012).   
Colon CAFs produce significant amounts of IL-6 and CRC cells 
further enhance IL-6 product ion by CAFs. IL-6 is a mult ifunct ional 
cytokine that plays a central role in the regulat ion of inflammatory 
and immune responses, but it  is also characterized as an angiogenic 
cytokine. CAFs play a crucial role for angiogenesis through 
secret ion of various cytokines (Goh et al. 2007). VEGF that is 
induced by IL-6 and several other factors (FGF, PDGF, and SDF-1) 
promotes angiogenesis. IL-6 was suggested to stimulate VEGF 
secret ion by the mediat ion of PGE-2 from CAFs. Secreted VEGF 
from fibroblasts targets endothelial cells and is known as one of the 
most important angiogenic factors (Nagasaki et al. 2014).  CAF-
derived TGF-β and connect ive t issue growth factor (CTGF) leads to 
proliferat ion through the SMAD2/SMAD4 pathway (Nakagawa et al.  
2004, Peddareddigari et al. 2010, De Boeck et al. 2013).   
CAFs are also able to secrete plasminogen act ivators as well as 
several members of the MMP family.  These enzymes may be 
exploited essent ially for two purposes: 1) direct degradat ion o f 
ECM, obviously associated with tumor expansion, invasion and 
angiogenesis, 2) cleavage of growth factors, pro-inflammatory 
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cytokines and their receptors, commonly associated wit h their 
act ivat ion, or cleavage of cell adhesion molecules, leading to 
increase motility and epithelial –mesenchymal transit ion (EMT) 
(Hynes 2009, Roy et al. 2009).  
The role of CAFs in tumor progression is mult ifaceted (Mueller & 
Fusenig 2004).  Similarly to immune cells, which init ially repress 
malignant growth, CAFs inhibit early stages of tumor progression, 
mainly through the format ion of gap junctions between act ivated 
fibroblasts. Conversely, later on CAFs become act ivated by several 
tumor secreted factors and promote both tumor growth and 
progression (Nakagawa et al. 2004)  (Figure 5). 
 
 
Figure 5. Hallmarks of cancer regulated by CAFs. From Hanahan & Weinberg 2011. 
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Two closely interact ive pathways are established in the crosstalk 
between cancer and stromal cells: a) in the “efferent” pathway, 
cancer cells trigger a react ive response in the stroma, and b) in the 
“afferent” pathway, the modified stromal cells in the surrounding 
microenvironment affect cancer cell responses (De WO & Mareel 
2003, Giannoni et al. 2010).  
CAFs support cancer stem cells (CSCs) that are maintained in a 
quiescent state and are resistant to chemotherapy and radiat ion (Li & 
Bhat ia 2011). In a recent study, Vermeulen and colleagues described 
a novel link between CRC stem cells and myofibroblasts, showing 
that myofibroblast-derived HGF act ivated CRC Wnt signalling and 
restored the stem cell phenotype in more different iated cells 
(Vermeulen et al. 2010). These data suggest that the 
microenvironment is a crit ical regulator of the ste m cell niche. 
Many clinical and experimental data also support the notion that 
fibroblasts play crucial roles in immune responses through 
production of cytokines and chemokines (Bucala et al. 1991). 
Furthermore, fibroblasts not only mediate the quality but  also the 
quant ity of the immune response (Parsonage et al.  2003). In normal 
physiology, fibroblasts can terminate immune responses by 
withdrawing survival signals and normalize the chemokine gradients 
which accelerate the apoptosis or withdraw the tissue through the 
lymphat ic vessels (Buckley et al. 2001). Pro -inflammatory cytokines 
are secreted by cancer cells and CAFs attract excessive immune 
cells to the cancer region. Macrophages, neutrophils and 
lymphocytes could be recruited to the tumor stroma by secret ing 
factors from the CAFs. Macrophages are actively attracted into 
tumor regions along defined chemotact ic gradients and release a 
number of factors that influence endothelial cell behavior including 
VEGF, HGF, MMP2 and IL-8. Once macrophages reach the tumor, 
they start to different iate into tumor-associated macrophages 
(TAMs) which further enhance the growth and metastasis of cancer 
cells (Leek & Harris 2002).  
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Stromal cells are the main source of thrombospondin-1(TSP-1) 
which has both posit ive and negat ive effects on angiogenesis and 
interact ion with immune cells (Li et al. 2007). As ment ioned 
previously, CAFs excessively secrete MMPs which degrade 
basement membrane and cleaved products of MMPs such as 
fibronect in and collagen (Brundula et al. 2002).  
In colorectal cancer, CAFs-derived condit ioned medium and 
exosomes promoted clonogenicity and tumor growth of cancer stem 
cells (CSCs) upon treatment with 5-fluorouracil or oxaliplat in (Hu et  
al. 2015). Mult iple CAF-derived factors sustain proliferat ive 
signaling in CRC cells and support the cancer cells to resist cell 
death (Kalluri & Zeisberg 2006, Tlsty 2001, Liotta & Kohn 2001) 
and evade growth suppressors. Consequently, it  is suggested that 
CSCs are correlated with recurrence and metastasis of cancer.  
Chemotherapy-treated CAFs maintain cancer-init iat ing cells (CICs) 
and their drug resistance through secret ion of IL-17A (Lotti et al.  
2013).  
Nonetheless, the mechanisms underlying the effects of CAFs on 
cancer progression are st ill unclear. Thus, elucidat ion of these 
mechanisms is likely to lead to new ant icancer treatments target ing 
CAFs and the cancer-stroma interact ion (Shiga et al. 2015).  
 
1.4.3 CAFs markers 
To date, fibroblasts have been difficult  to posit ively ident ify. In 
some cases, fibroblasts are ident ified based on their spindle shape 
combined with posit ive staining for the mesenchymal marker 
viment in and the absence of staining for epithelial or other 
mesenchymal cell types, such as muscle cells, astrocytes, or 
hematopoiet ic cells (Chang et al. 2002). However, this approach is 
hardly definit ive. Fibroblasts can take on a wide array of shapes in 
different tissues, whereas viment in-posit ive cells that are not 
fibroblasts, including macrophages can also have a spindle-shaped 
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appearance. Furthermore, viment in stains a large number of cell 
types, making it difficult to ident ify fibroblasts by eliminat ion 
(Goodpaster et al. 2008).  
The most widely used marker for CAFs is α -smooth muscle act in (α-
SMA). Upon tissue damage, fibroblasts proliferate and diffe rent iate 
into myofibroblasts. These myofibroblasts acquire de novo 
expressed α-SMA, contractile stress fibers, and the ED-A splice 
variant of fibronect in (Tomasek et al. 2002, Serini et al. 1998). As 
there are more myofibroblasts in the tumor stroma, α-SMA is widely 
used as a CAF marker (Orimo et al. 2007, Sappino et al. 1988). α -
SMA has been demonstrated not to label CAFs exclusively,  but also 
smooth- muscle cells in the muscularis mucosae and muscularis 
propria (Herrera et al. 2013, Harper & Sainson 2014) .  
Another useful marker for CAFs is fibroblast act ivat ion protein 
(FAP) (Park et al. 1999, Kraman et al. 2010). FAP appears to be 
expressed on pericytes and CAFs (Harper & Sainson 2014). High 
intratumoral expression of FAP is associated with poor prognosis in 
colorectal cancer (Wikberg et al. 2013). Nonetheless, the t issue 
distribut ion and funct ion of FAP-α are not restricted to stromal 
fibroblasts: its expression is detectable in epithelial malignant cells 
(Ment lein et al. 2011, Dohi et al. 2009).  
Several other markers have also been reported in pre vious studies,  
such as tenascin-C (Yoshida et al. 2015), periost in (Kikuchi et al.  
2008), neuron glial ant igen-2 (NG2) (Sugimoto et al. 2006),  
viment in, desmin, platelet derived growth factor receptor -α and β 
(PDGFR α and β) and fibroblast specific protein-1 (FSP-1) 
(Sugimoto et al. 2006). Quiescent resident fibroblasts express 
viment in, instead of a-SMA, as intermediate filament proteins 
(Tsujino et al.  2007). These markers are not necessarily specific for 
myofibroblasts. Individually, these markers could ident ify specific 
subpopulat ions of fibroblasts, thus it would be more correct to use a 
combinat ion of markers to select the largest possible populat ion of 
CAFs (Herrera et al. 2013).  
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On the other hand, cytokerat in and CD31 are considered negat ive 
markers, as CAFs do not have epithelial and endothelial 
characterist ics (Xing et al. 2010, Sukowati et al. 2015).  
An exclusive marker for CAFs that can clearly dist inguish them 
from normal fibroblasts from adjacent mucosa or other closely 
related cell types is yet to be ident ified.   
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2. AIMS OF THE STUDY 
 
It has been shown that in cancer, stromal gene dysregulat ion 
contributes more to poor prognostic molecular signatures than the 
epithelium itself (Calon et al. 2015, Isella et al. 2015), supporting 
the fact that the tumor stroma influence cancer epithelial cell 
behavior.  
Thus, the focus of this thesis has been to try to understand the role 
of the stroma in CRC init iat ion and progression. In order to do that:  
 DEG in the epithelial and stromal compartment of two CRC 
human precancerous lesions,  have been studied; 
 
 DEG in the epithelial and stromal compartment of two CRC 
mouse models of precancerous lesions have been analyzed;  
 
 primary human fibroblast cells from normal colonic t issue, 
adenomas and CRC pat ients have been isolated and 
characterized; 
 
 transwells and 3D co culture technics have been used to 
assess the influence of normal and neoplasia associated 
fibroblasts on epithelial cell behaviour/expression and vice 
versa.  
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3. MATERIALS AND METHODS 
 
In order to characterize the transcriptome of the epithelial and 
stromal compartment of two CRC human precancerous lesions, SSA 
and TVA, a cohort of these polyps has been collected.  
 
3.1 Human Normal and Polyps (TVAs, SSAs) sample collection 
for EDTA separation 
Human polyp t issues samples (TVAs, SSAs) were obtained from 
patients undergoing colonoscopy at John Radcliffe Hospital, Oxford 
with local REC approval (REC 10/H0604/72) (Figure 6). Written 
informed consent was obtained from all donors.  
 
 
Figure. 6. Representative TVA and SSA before endoscopic resection. 
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A cohort of SSAs (n=24) and TVAs (n=24) with neighboring normal 
tissue (n=24) was collected.  
1mm3 biopsies were collected to be analyzed and the rest of the 
lesion has been processed for histological  assessment thus clinical 
pathological assessment of the lesions will be unaffected.  
Table 4 shows the characterist ics of the samples collected for this 
study.  
 
Patient Organ Region Tissue Status 
1 Colon Rectum Normal Polyp (SSA) 
2 Colon Transverse Normal Polyp (SSA) 
3 Colon Ascending Normal Polyp (SSA) 
4 Colon Ascending Normal Polyp (SSA) 
5 Colon Rectum Normal Polyp (SSA) 
6 Colon Ascending Normal Polyp (SSA) 
7 Colon Caecum Normal Polyp (SSA) 
8 Colon Ascending Normal Polyp (SSA) 
9 Colon Ascending Normal Polyp (SSA) 
10 Colon Ascending Normal Polyp (SSA) 
11 Colon Caecum Normal Polyp (SSA) 
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12 Colon SplenicFlexure 
Tranverse 
Normal Polyp (SSA) 
13 Colon Ascending Normal Polyp (SSA) 
14 Colon Caecum Normal Polyp (SSA) 
15 Colon Caecum Normal Polyp (SSA) 
16 Colon Transverse Normal Polyp (SSA) 
17 Colon Rectum Normal Polyp (SSA) 
18 Colon Ascending Normal Polyp (SSA) 
19 Colon Rectum Normal Polyp (SSA) 
20 Colon Ascending Normal Polyp (SSA) 
21 Colon Caecum Normal Polyp (SSA) 
22 Colon Ascending Normal Polyp (SSA) 
23 Colon Caecum Normal Polyp (SSA) 
24 Colon Caecum Normal Polyp (SSA) 
25 Colon Caecum Normal TubVilAdenoma 
26 Colon Transverse Normal TubVilAdenoma 
27 Colon Rectum Normal TubVilAdenoma 
28 Colon Hepatic Flexure Normal TubVilAdenoma 
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29 Colon Rectum Normal TubVilAdenoma 
30 Colon Hepatic Flexure Normal TubVilAdenoma 
31 Colon Caecum Normal TubVilAdenoma 
32 Colon Caecum Normal TubVilAdenoma 
33 Colon Transverse Normal TubVilAdenoma 
34 Colon Caecum Normal TubVilAdenoma 
35 Colon Rectum Normal TubVilAdenoma 
36 Colon Hepatic Flexure Normal TubVilAdenoma 
37 Colon Rectum Normal TubVilAdenoma 
38 Colon Hepatic Flexure Normal TubVilAdenoma 
39 Colon Caecum Normal TubVilAdenoma 
40 Colon Hepatic Flexure Normal TubVilAdenoma 
41 Colon Caecum Normal TubVilAdenoma 
42 Colon Caecum Normal TubVilAdenoma 
43 Colon Transverse Normal TubVilAdenoma 
44 Colon Caecum Normal TubVilAdenoma 
45 Colon Rectum Normal TubVilAdenoma 
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46 Colon Hepatic Flexure Normal TubVilAdenoma 
47 Colon Rectum Normal TubVilAdenoma 
48 Colon Hepatic Flexure Normal TubVilAdenoma 
Table 4. Cohort of collected SSAs and TVAs with neighboring normal tissue. 
 
3.2 Mouse sample collection for EDTA separation  
The same analysis was performed in mice models of adenomas to 
see if the results obtained in human adenomas were reproducible in 
mice models.  
 
3.2.1 Mouse procedures 
All procedures were carried out in accordance to Home Office UK 
regulat ions and the Animals (Scient ific Procedures) Act 1986. All 
mice were housed at the animal unit at Funct ional Genomics 
Facility, Wellcome Trust Centre for Human Genet ics , Oxford 
University. All strains used in this study were maintained on 
C57Bl/6J background for ≥ 6 generat ions.  
 
3.2.2 Inducible transgene model Cre  
The most popular method for inducible transgene expression is the 
Cre-ERT2 system that was established in the 1990s (Nagy 2000). In 
this technic, mice carrying a Cre transgene (under the control of an 
inducible t issue specific promoter) are crossed to mice bearing an 
inducible allele where the region that is to be deleted is flanked by 
LoxP recombinat ion sites (Jackstadt & Sansom 2016). This can be 
either an essent ial exon(s) of a gene, to produce a condit ional 
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knockout, or a Stop motif that act ivate an oncogene within adult  
tissue (Sansom et al. 2006, Jackson et al. 2001).  
In this study, the Cre-ERT2 fusion protein has been expressed under 
the control of the Villin promoter (Beuling et al. 2011, El Marjou et 
al. 2004) and the Lgr5 promoter (Barker et al. 2007). While Cre -
ERT2 has proven very effect ive at inducing precisely t imed delet ion 
of floxed alleles in the intest ine when linked to these promoters, the 
liability of this approach is that it  requires inject ion of a potent 
estrogenic compound (tamoxifen) (Hayashi & McMahon 2002).  
For this study, inducible Cre C57bl/6j mice were treated with 1 mg 
tamoxifen by intra peritoneal inject ion for five days to introduce 
Apc fl / fl  and BrafV600E mutat ions specifically into adult  mouse 
epithelium.  
Thus, VillinCreERT2; Apc fl / fl and VillinCreERT2; BrafV600E mice 
models were used to reproduce the molecular et iology, pathology 
and clinical progression of the human TVAs and SSAs precursors 
lesions respect ively. As described above the epithelium and the 
stroma were separated, isolated and the RNA was extracted for the 
genes expression analysis.  
 
3.3 Gene expression analysis  
3.3.1 Individual crypt and villus isolation, RNA extraction  
Human and mouse individual crypts and villus were isolated 
following Leedham et al. protocol (Leedham et al. 2013). Briefly,  
biopsies were washed with PBS and incubated in 5 ml dissociat ion 
media (30 mM EDTA in DMEM without Ca2+ and Mg2+, 0.5 mM 
DTT, 2% RNA later (Life Technologies) for 10 min at room 
temperature.  
Immersion in culture medium containing EDTA allows separat ion of 
epithelium from the underlying stroma.  
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The digested t issue was then transferred to PBS and shaken 
vigorously for 30 s to release individual crypts and villi. Individual 
structures were selected using a drawn out glass pipette under a 
dissect ion microscope and transferred to RLT buffer ready for 
subsequent RNA extract ion with the RNeasy microkit (Qiagen) 
according to manufacturer’s instruct ions. RNAs were treated with 
DNase I (Sigma) to degrade residual DNA (Figure 7). The purity and 
concentration of the RNA samples were determined using NanoDrop 
ND-1000. 
 
 
Figure 7. Epithelial and stromal separation from colonic tissue for gene expression profiling. 
 
 
3.3.2 Gene expression arrays  
Gene expression RNA from each sample was checked for quality on 
the Agilent 2100 Bioanalyzer. Linear RNA amplificat ion was carried 
out using TargetAmp™ 2-Round Biot in-aRNA Amplificat ion Kit 3.0 
(Epicentre, Illumina). 20-100ng of total RNA from each sample was 
passed onto WTCHG Oxford Genomics Centre where hybridizat ion 
on human Illumina Whole-Genome Gene Expression Beadchips.  
These plat forms allow to  capture a broad range of gene expression 
changes and detect changes in novel transcripts between the 
experimental samples and the controls. Raw data from Illumina gene 
expression arrays were processed after removing outlier samples 
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from init ial quality control using the VSN (variance-stabilisat ion 
and normalisat ion) algorithm. A filter was applied by taking a 
detection score of > 0.95 of the background intensity distribut ion for 
all samples to consider a probe detectable.  
 
3.3.3 Bioinformatic analyses 
Following, the bioinformatic analyses data normalizat ion were 
performed and were carried out using the Linear Models for 
Microarray Data (Limma) by Bioconductor (available at: 
www.bioconductor.org/packages/2.3/bioc/html/limma.html). 
Different ially expressed genes were ident ified using Student’s t -test 
by running “ttest2” command in MATLAB®. Four lists of 
different ially expressed gene (DEG) were generated for the 
comparsonsof the RNA expressed in the experimental groups with 
the controls groups.  
Gene Set Enrichment Analysis (GSEA) was performed using 
Kolmogorov-Smirnov statist ics and gene shuffling permutations.  
Pathway enrichment analyses using DAVID Bioinformatics 
Resource 6.7 (NIH) (Huang et al. 2009) and Ingenuity Pathway 
Analysis (www.ingenuity.com) were used to analyze the gene 
expression data. Genes were ranked by computing their different ial 
expression in the experimental versus normal samples by the 
Student’s t-test method. If mult iple probes were present for a gene, 
probe with the highest absolute differential expression between 
experimental and normal was selected. Gene shuffling with 1,000 
permutat ions to compute the P-value for the enrichment score was 
used.  
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3.4 Human Normal, Polyps and CRC sample collection for 
fibroblasts isolation 
The results got from the characterizat ion of the epithelial and 
stromal compartment in human and mouse adenomas led to the study 
of the stroma major cell component, the fibroblasts.  
In order to do that, fresh surgical human t issue samples were 
obtained with informed consent from different adults who underwent  
surgical resect ion for colon cancer (CMS 2 and CMS 4) at the 
Churchill Hospital. The normal colonic mucosa, the central part and 
the leading edge (LE) of the tumor where collected from all the 
patients. Biopsies selected from the same specimens were distal 
from the outer margin of the cancers masses.  
Polyp t issues samples (TVAs, SSAs) were obtained from pat ients 
during routine endoscopy by at the John Radcliffe Hospital. The 
samples are collected from either male or  female pat ients and used 
without regard to sex. Written informed consent was obtained from 
all donors. The tumor characterist ics of all the pat ients are listed in 
Table 5.  
 
Patient Sex Age 
(years) 
Sample Type Polyp/ Tumor site 
1 Male 71 Normal Ascending 
2 Male 65 Normal Transverse 
3 Male 75 Normal Descending 
4 Female 65 Normal, Central, Leading 
Edge 
Recto-sigmoid junction 
5 Male 79 Normal, Central, Leading 
Edge 
Cecum Right hemicolectomy 
6 Male 77 Normal Ascending 
7 Male 74 Normal, Central, Leading 
Edge 
Right hemicolectomy 
Hepatic flexure 
8 Female 65 Normal Descending 
9 Female 34 Normal, SSA Sigmoid 
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10 Male 67 Normal, TVA Ascending 
11 Female 36 Normal, SSA 1, 2 Ascending 
12 Male 66 Normal, TVA Sigmoid 
13 Female 80 Normal, Central, Leading 
Edge 
Left hemicolectomy Sigmoid 
14 Female 67 Normal, SSA Splenic 
15 Female 80 Normal, TVA Transverse 
16 Male 84 Normal, Central, Leading 
Edge 
Cecum Pole- Right 
hemicolectomy 
17 Male 61 Normal, TVA (40 mm) Recto-sigmoid junction 
18 Female 79 Normal, Central, Leading 
Edge 
Right hemicolectomy 
Hepatic flexure 
19 Male 61 Normal, Central, Leading 
Edge 
Left hemicolectomy Sigmoid 
20 Female 83 Normal, TVA Ascending 
21 Female 56 Normal, SSA Ascending 
22 Male 79 Normal, Central, Leading 
Edge 
Sigmoid 
23 Male 71 Normal, TVA (90 mm) Descending 
24 Female 64 Normal, SSA (10 mm) Descending 
25 Male 73 Normal, Central, Leading 
Edge 
Cecum Right hemicolectomy 
26 Male 36 Normal, SSA 1, 2, 3 Transverse 
27 Male 72 Normal, TVA (4 cm) Ascending 
28 Male 56 Normal, TVA Ascending 
29 Male 76 Normal, TVA Sigmoid 
30 Female 67 Normal, SSA Hepatic Flexure 
31 Female 69 Normal, SSA (30 mm) Sigmoid 
32 Female 38 Normal, SSA ( 25 mm) Transverse 
33 Male 70 Normal, TVA (10 mm) Transverse 
34 Male 68 Normal, TVA  (4 cm) Sigmoid 
351 Female 65 Normal, TVA (2 cm) Rectum 
36 Female 87 Normal, SSA (31 mm) Sigmoid 
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372 Male 24 Normal, TVA (10mm) Sigmoid 
38 Male 90 Normal, TVA (40mm) Rectum 
39 Female 51 Normal, TVA (12mm) Sigmoid 
40 Female 58 Normal, SSA 1 (25 mm), 
SSA 2 (18 mm) 
Transverse 
41 Female 71 Normal, TVA (30 mm) Ascending 
42 Male 85 Normal, SSA (25 mm) Sigmoid 
43 Female 65 Normal, TVA (20 mm) Sigmoid 
44 Male 72 Normal, TVA (35 mm) Recto-Sigmoid Junction 
45 Female 51 Normal, SSA (20 mm) Sigmoid 
463 Male 74 Normal, SSA (12 mm) Hepatic Flexure 
47 Male 36 Normal, SSA (13 mm) Ascending 
48 Female 87 Normal, TVA (35mm) Rectum 
49 Male 78 Normal, SSA (15 mm) Transverse 
50 Female 68 Normal, TVA (23 mm) Sigmoid 
Table 5. Characteristics of patients and patient tumours. 1Adenocarcinoma of the sigmoid 
and liver methastasis; 2More than 300 polyps; 3Resection of lung methastasis and CRC in 
2012. 
 
 
 
3.4.1 Isolation and culture of primary fibroblastic population  
During colonoscopy and surgery, t issue specimens were taken and 
rapidly dipped into sterile tubes containing 5 mL of medium 
composed by DMEM supplemented with 10% fetal bovine serum 
(Sigma), 1% penicillin/streptomycin (Sigma), Neomycin solut ion 
0.05 mg/ml (Sigma), 1% Fungizone: gibco® amphotericin B 2.5 
ug/ml (Gibco), Gentamycin 0.04 mg/ml (Sigma), Ciprofloxacin 10 
ug/ml (Sigma) during the transport from the endoscopy room to the 
cell culture laboratory (approximately 25 minutes).  
At the laboratory, biopsy samples were gent ly washed in phosphate 
buffered saline (PBS) for several t imes to remove blood and moved 
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into a tissue culture dish (60 × 15 mm) and finely chopped into 
small pieces (1-2 mm) with a disposable surgery knife for 
approximately 5 minutes; samples were incubated in DMEM (serum 
free, 1% penicillin/streptomycin (Sigma) containing collagenase 
type IV (225 units/ml; Sigma) at 37˚C for 3 hours in a shaker.  
Then, the digested tissue was centrifugated (1000 × g for 5 minutes) 
and resuspended in DMEM supplemented with 2 mM L-glutamine, 
1% penicillin/streptomycin (Sigma), Neomycin solut ion 0.05 mg/ml 
(Sigma), 1% Fungizone: gibco® amphotericin B 2.5 ug/ml (Gibco),  
Gentamycin 0.04 mg/ml (Sigma), Ciprofloxacin 10 ug/ml (Sigma) 
and 10% fetal bovine serum (Sigma) that stopped the enzymatic 
act ivity of the collagenase.  
The obtained t issue pieces and float ing cells were seeded onto the 
cell culture Petri dishes (35 × 10 mm) in 2 mL of medium composed 
by DMEM supplemented with 2 mM L-glutamine, 10% fetal bovine 
serum (Sigma), MEM Non-essent ial Amino Acid Solut ion (Sigma), 
1% penicillin/streptomycin (Sigma), Neomycin solut ion 0.05 mg/ml 
(Sigma), 1% Fungizone: gibco® amphotericin B 2.5 ug/ml (Gibco),  
Gentamycin 0.04 mg/ml (Sigma), Ciprofloxacin 10 ug/ml (Sigma).  
The fibroblast cultures were established and maintained at 37°C in 
primaria plates (Corning).  
As previously described for other types of fibroblast (Cristofalo & 
Pignolo 1993, Cristofalo et al. 1998, Montalto et al. 1999,  
Pourreyron et al.  2003), colon fibroblasts undergo a phase of 
senescence after an init ial phase of growth. Normal human mitotic 
cells do not proliferate indefinitely in culture but undergo a limited 
number of divisions and progressively reach a state of irreversible 
growth arrest, a process termed replicat ive senescence caused by 
react ive oxygen species which are known to apply a genotoxic stress 
and induce senescence (Nair et al. 2015).  
For these reasons, I cultured them in a humidified atmosphere 
containing 5% CO2 and 3% O2. In this way senescence was delayed 
and they could be kept in culture unt il cell passage number 18 (P18).  
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The medium was replaced after 6 days and the Ciprofloxacin was 
removed from the media after 21 days when the cells were tested for 
mycoplasma contaminat ion. All the cells treated as described above 
were mycoplasma free.  
When confluent, st romal cells were harvested using 0.1% Trypsin-
EDTA (Sigma Aldrich) and split at ratios of 1:3–1:5. Stromal 
cultures were expanded using primaria T75 flasks and a ll the 
different isolated fibroblast s were frozen down and stored in liquid 
nitrogen for future experiments.  
 
3.4.2 Preparation of fibroblasts conditioned media  
Normal, adenomas (SSA, TVA) and CAFs were grown in fibroblasts 
culture media unt il they reached a confluency state of approximately 
85%. Then, the condit ioned media were collected, centrifuged at 
400×g for 10 min to remove float ing cells and cellular debris,  
subjected to sterile filtrat ion (pore size: 0.22 mm, Millipore) and 
protease treated and stored at -80°C unt il use. 
 
3.4.3 Fibroblasts characterization  
3.4.3.1 qRT-PCR  
Total RNA from the cultured fibroblasts was extracted to verify the 
real nature of the fibroblast by performing qRT-PCR for the 
fibroblasts marker viment in.  
Briefly, the RNA was extracted and treated with DNase I as 
previously described. Complementary DNA was reverse transcribed 
in vitro using the High Capacity cDNA Reverse Transcript ion Kit  
(Applied Biosystems). When necessary, pre -amplificat ion of cDNAs 
was performed prior to qRT-PCR final step. The TaqMan PreAmp 
(Applied Biosystems) kit was used following manufacturer’s  
instruct ions. Absolute quant ificat ion qRT -PCR was performed in 
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triplicate using the ABI 7900HT cycler (Applied Biosystems) with 
GAPDPH/Gapdh serving as an endogenous control.  
The primary assumption in analyzing Real time PCR results is that 
the effect of a gene can be adjusted by subtract ing Ct number of 
target gene from that of the reference gene (ΔCt). The deltaCt for 
experimental and control can therefore be subject to t -test, which 
will yield the est imat ion of ΔΔCt. In all cases the data met the 
normal distribut ion assumption of the t -test. 
 
3.4.3.2 Immunocytochemistry 
In cell passage 5, the purit ies of the various fibroblast populat ions 
were verified through immunostaining.  
For the immunostaining experiments, the cells were cultured 
overnight on chamber slides, fixed with 4% paraformaldehyde, 
washed twice in PBS and fixed with 4% formaldehyde in PBS for 20 
minutes at room temperature (RT). Fixed cells were blocked with 
10% serum for 30 minutes. Slides were incubated with primary 
ant ibody for 2 hours: ant i-viment in (1:50, CST), ant i-α-smooth 
muscle act in (α-SMA) (1:1000, Sigma), ant i-desmin (1:500, Abcam). 
Epithelial types were carefully excluded performing ant i-human 
cytokeratin 20 immunocytochemistry (1:200; Abcam) (Table 6).  
Appropriate secondary ant ibodies were applied for 1 h at room 
temperature. Sections were then incubated in ABC (Vector labs) for 
30 minutes. The chamber was removed using the supplied tool and 
DAB solut ion was applied for 2–5 minutes and development of the 
colour react ion was monitored microscopically. Slides were 
counterstained with haematoxylin, dehydrated, cleared and then 
mounted.  
To quant ify the percentage of posit ive cells, the posit ive cell 
numbers relat ive to the total cell numbers (>100 counted cells) were 
evaluated in 10 independent fields from three different wells of each 
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fibroblast type. Images were taken with a Digital DS-L1 camera 
(Nikon).  
 
3.4.4 Identifying fibroblasts in formalin-fixed, paraffin-
embedded tissue 
In order to localize the fibroblast in the colonic t issue, 
immunohistochemistry analysis was performed in both human and 
mouse normal, precancerous and tumor paraffin- embedded tissue. 
 
3.4.4.1 Mouse and human tissue preparation and histology  
Wild type (n=3), VillinCreERT2Apc fl/ f l (n=3), and VillinCreERT2 ; 
BrafV600E (n=3), mice were sacrificed at pre-defined t ime points or 
when showing symptoms of intest inal polyps (anaemia, hunching) 
by cervical dislocat ion. The intest inal tract was removed 
immediately and divided into small intest ine (proximal/SB1, 
middle/SB2 and distal/SB3) and colon (Figure 8). The intest ines 
were opened longitudinally, using a gut preparat ion apparatus,  
washed in PBS, fixed overnight in 10% neutral buffered formalin 
(NBF). Specimens of 10% formalin-fixed tissue were embedded in 
paraffin following standard protocols.  
Paraffin-embedded t issues were cut at 4 μm with the microtome and 
placed on posit ively charged slides and baked over night (O.N.) at 
60°C. Then, deparaffinized and rehydrated through xylenes and 
graded alcohols to water.  
 
91 
 
 
Figure 8. Correspondences between mouse and human gut. Adapted from Leedham et al. 
2013. 
 
Following the same protocol, fresh human colonic normal (n=3),  
SSA (n=3), TVA (n=3) and CRC (n=3) collected tissue samples were 
processed for IHC. 
 
3.4.4.2 H&E 
On the 4 µm sect ions hematoxylin-eosin staining was performed 
using common protocols. Briefly, sect ions were previously dewaxed 
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in xylene and rehydrated through graded alcohols to water. Then, 
each sect ion was treated with the Hematoxylin dye (Merk) that 
stains of blue-violet nuclei for 30 seconds, washed in running water 
unt il clear, followed by a quick dip in acid alcohol and contrasted 
for 5 minutes in tap water. The sect ions were treated with eosin 
(Merck) that stains pink the cytoplasm, for 3 minutes and washed 
again quickly in tap water, dehydrated, cleared and then mounted.  
 
3.4.4.3 Immunohistochemistry 
Formalin-fixed, paraffin-embedded t issue sect ions (4 μm) were 
dewaxed in xylene and rehydrated through graded alcohols to water. 
Endogenous peroxidase was blocked using 1.6% H 2O2 for 20 
minutes. For ant igen retrieval, sect ions were pressure cooked in 10 
mmol/L citrate buffer (pH 6.0) for 5 minutes. Sect ions were blocked 
with 10% serum for 30 minutes. Slides were incubated with primary 
ant ibody for 2 hours.  
The following ant ibodies have been used in this study: ant i-viment in 
(1:50, CST), anti-α-smooth muscle act in (α-SMA) (1:1000, Sigma),  
ant i-desmin (1:500, Abcam), ant i-human cytokeratin 20 (1:200; 
Abcam), ant i-Ki-67 (1 :125, Dako), ant i-Alkaline Phosphatase (1:50, 
Abcam),ant i- lysozyme (1:500, Dako) and ant i-chromogranin A 
(1:1.1250, Abcam) (Table 6). Appropriate secondary ant ibodies were 
applied for 1 h at room temperature. Sections were then incubated in 
ABC (Vector labs) for 30 minutes. DAB solut ion was applied for 2–
5 minutes and development of the colour reaction was monitored 
microscopically. Slides were counterstained with haematoxylin,  
dehydrated, cleared and then mounted. Images were taken with a 
Digital DS-L1 camera (Nikon). 
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Antigen Antibody type Clone Code Manufacturer Dilution 
Citocheratin 20 Rabbit 
polyclonal 
- Ab 
118574 
Abcam 1:200 
αSMA  Mouse 
monoclonal 
1A4 A5228 Sigma-Aldrich 1:1000 
Desmin   Rabbit 
polyclonal 
- Ab 15200 Abcam 1:500 
Vimentin Rabbit 
monoclonal 
D21H3 5741 CST 1:50 
Table 6. Antibodies used in ICC and IHC. 
 
 
3.5 In vitro organoids co culture experiments 
The final aim of the thesis was to try to elucidate the fibroblasts 
influence on epithelial cells and vice versa. For this analysis,  
different co culture techniques were used.  
In particular, co culture is one of culture methodologies that have 
been performed for the purpose of analyzing epithelial–stromal 
interact ions in vitro. Moreover, for this study, I used cell culture 
inserts with translucent porous membranes that keep the co -
cult ivated cell populat ions separated (Figure 9). The membrane 
material is polyester, which is clear film and can direct ly examine 
the cells under the light microscopy. Pore sizes and their density o f 
membrane are 0.4 µm.  
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Figure 9. Schema of co-culture system. The membrane separate each cell and allows the 
cell–cell interactions through the soluble factors cell derived. Adapted from Miki et al. 2012. 
 
 
 
3.5.1 Small intestinal crypt isolation 
The first co culture experiments was performed using small 
intest inal organoids that display all hallmarks of the small intest inal 
epithelium in terms of architecture, cell type composit ion, and self-
renewal dynamics.  
The protocol used for the isolat ion of mouse intest inal crypts and 
organoid culture was adapted from Sato and Clevers (Sato & Clevers 
2013) and it is schematically represented in Figure 10. 
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Figure 10. From intestinal epithelial crypt isolation to organoid cultures. From Lukovac et al. 
2014. 
 
 
On the day of the experiments, before performing crypt isolat ion, 
several aliquots of Matrigel™ Basement Membrane Matrix (BD 
Biosciences) were thawed on ice and the 24-well plates were pre-
incubate in a CO2 incubator (5 % CO2, 37°C).  
Matrigel™ is a solubilized gelat inous protein mixture and is derived 
from the Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells. The 
extract resembles the complex extracellular environment found in 
many t issues and is commonly used as a substrate for culturing 
cells. Isolated intest inal cells undergo anoikis outside the normal 
tissue context (Hofmann et al. 2007) and the matrigel support 
intest inal epithelial growth (Sato et al. 2011, Sasaki et al. 2002) . At 
room temperature, matrigel polymerizes into a three dimensional 
structure that is useful for both cell culture and studying cellular 
processes in three dimensions, including cell migrat ion.  
Two C57bl/6j wild type mice were sacrificed and the small 
intest ines were taken (at least 5 cm) and opened longitudinally as 
previously described. The intest ine was washed with ice cold 
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phosphate-buffered saline (PBS) unt il most of the luminal contents 
were cleared and scraped off the villi using a coverslip.  
After another washing with ice-cold PBS, the intest ine was cut into 
2–4 mm pieces with scissors and transferred to a 50-mL tube. 30 mL 
of ice-cold PBS were added and the fragments were washed by 
gent ly pipetting them up and down with a 10 mL pipette. The 
supernatant was discarded after settling down. This step was 
repeated for 10 times unt il the supernatant was almost clear.  
Next, 25 mL of ice-cold crypt isolat ion buffer (2.5 mM EDTA in 
PBS) were added and the tube was gent ly rocked at 4 °C for 30 
minutes. After settling down the fragments, the supernatant was 
removed and 10 mL of ice-cold basal culture medium (advanced 
Dulbecco’s modified Eagle medium/F12 (Life Technologies) 
supplemented with penicillin/streptomycin (Sigma  Aldrich), 10 
mmol/L HEPES (Sigma Aldrich), Glutamax, 1% N2 (Life 
Technologies), 10 ml B27 (Life Technologies) and 1 mmol/L N –
acetylcysteine (Sigma Aldrich) were added to wash the fragments 
using a pipette.  
When the fragments were settled down, this procedure was repeated 
in order to release most of the crypts that  were also settling down 
after some t ime. Villous fract ions present in the supernatant were 
discarded and crypts fract ions were passed through a 70-mm cell 
strainer and collected into 50 mL tube. The crypt fract ions was spin 
down at 800×g for 5 minutes and the pellets were resuspended in 10 
mL of ice-cold basal culture medium. The suspension was 
transferred to a 15 mL Falcon tube and centrifuged at 600×g at 4ºC 
for 2 minutes to remove single cells (mostly lymphocytes), which 
end up in the supernatant.  
It  should be noted that at this point it  is difficult to dist inguish true 
crypts from other epithelial debris and the count is only a rough 
est imate. 
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3.5.2 Ex vivo culture of intestinal crypt organoids  
Small intest inal crypts were centrifuged and, as much as possible,  
supernatant was removed to avoid dilut ion of Matrigel™ in the next  
step. The tube kept at 4°C and the crypts pellet was resuspended in 
Matrigel™ (50 µl basal media/100 μl Matrigel™). 35 μL of the 
crypt-Matrigel™ suspension were placed into the pre-warmed 24-
well plate. The suspension was applied on the center of the transwell 
so a hemispherical droplet can be formed. The plate was transfer 
back into the CO2 incubator (5 % CO2, 37 °C) as soon as possible 
after the seeding. After 10 minutes, the Matrigel™ was solidified 
and 500 μL of complete organoid culture medium was added per 
well: Epidermal Growth Factor (EGF) (Life Technologies) at 50 
ng/ml, R-spondin-1(R&D systems) at 500 ng/ml and Noggin at 100 
ng/ml (PeproTech) (Table 7 and Table 8).  
Under this culture condit ion (R-spondin-1, EGF, and Noggin in 
Matrigel™), small intest inal organoids were established with the 
purpose to display all hallmarks of the small intest inal epithelium in 
terms of architecture, cell type composit ion, and self-renewal 
dynamics. 
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 STOCK 
CONCENTRATION 
FINAL 
CONCENTRATION 
FOR 500 ml 
MEDIA 
ADVANCED DMEM/ F12   470~ ml 
GLUTAMAX 200 mM 2 mM 5 ml 
Pen/Strep 100 X  5 ml 
N2 100 X 1X 5 ml 
B27 50 X 1X 10 ml 
N-ETYLCYSTEINE 500 mM 1 mM 1 ml 
HEPES 1M 10 mM 5 ml 
Table 7. Basal culture medium for mouse organoid culture. 
 
 
  STOCK 
CONCENTRATION 
FINAL 
CONCENTRATION 
FOR 500 ml 
MEDIA 
NOGGIN 100 ug/ml 100 ng/ml 1 ul 
EGF 50 ug/ml 50 ng/ml 1 ul 
R-SPONDIN 100 ug/ ml 500 ng/ml 5 ul 
Table 8. Growth factors added to the basal media for mouse organoid culture. 
 
 
 
3.5.3 Fibroblasts and small intestine organoids co culture 
In order to assess the influence of the fibroblast to the epithelial 
compartment in vitro, the day before the experiment, primary normal 
(n=3), central (n=3), leading edge (n=3), SSA (n=3) and TVA (n=3) 
fibroblast ic stromal cells (Passage 3-12) were plated at 1x105  
cells/well in a 24 well plate (bottom). The cells were allowed to 
adhere overnight at 37 ◦C and 3% CO2.  
In all the co culture experiments, normal, central and leading edge 
derived fibroblasts were isolated from the same pat ients.  
The day of the experiment, wild type organoids were isolated as 
described above and plated on permeable transwells cell culture 
inserts with 0.4 µm pore size. After few hours, the  organoids were 
moved on the 24 well plate (top) with the fibroblasts. In these 
condit ions, the organoids were grown for 7 days in media 
supplemented with R-spondin-1 and lacking Noggin and EGF while 
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the controls were grown with the basal media supplemented with all  
the growth factors: R-spondin-1, Noggin and EGF (REN) at 37 °C 
and 5 % CO2.  
The organoid growth and proliferat ion was monitored on a daily 
basis and after 7 days of co culture, the organoids were counted and 
characterized by IHC.  
 
3.5.4 Passaging of organoids 
After the intest inal villi had been cultured and had grown into 
organoids, they were passaged by adding cold media to melt  the 
Matrigel™ and subsequent ly re-plat ing in fresh Matrigel™. For 
passage, the culture medium was replaced with fresh basal cu lture 
medium. Organoids and Matrigel™ were mechanically disrupted 
using a P200 pipette and transferred into a 15 ml falcon tube. 
Dissociated organoids were washed with 10 ml of basal culture 
medium and centrifuged at 200 g for 2 minutes. The supernatant wa s 
discarded, the pellet resuspended with Matrigel™ and culture 
medium was added as described above.  
 
3.5.5 Embedding of organoids  
To collect material for embedding, the Matrigel™ was melted by 
adding cold media and then mult iple wells were combined. The cells 
were fixed with 500 μl PFA was 30 min at room temperature, 
centrifuged at 5000 rpm and resuspended in 150 μl 2% agarose (in 
PBS). The paraffin embedded cell pellet was then processed and 
embedded using standard protocols.  
 
 
 
100 
 
3.5.6 Alcian-blue stain for goblet cells 
Sect ions were dewaxed in xylene for 5 minutes, then rehydrated 
through graded ethanols (100%, 90%, 70%) for 5 minutes each 
followed by 2 minutes in tap H20. Slides were then stained in alcian-
blue solut ion (Sigma) for 30 minutes and then washed in running tap 
H20 for 2 minutes, before being rinsed in dH20. Slides were then 
stained in nuclear fast red solut ion (Sigma) for 5 minutes and 
washed in running tap H20 for 1 minut. Slides were then dehydrated 
through degraded alcohols for 2–5 minutes each, before mount ing a 
coverslip with DPX. Images were taken with a Digital DS-L1 
camera (Nikon). 
 
3.5.7 Organoids immunohistochemistry  
Formalin-fixed, paraffin-embedded t issue sect ions (4 μm) were 
dewaxed following the same protocol previously described.  Slides 
were incubated with primary ant ibody for 2 hours. In part icular: 
ant i-Ki-67 (1:125, Dako), ant i-Alkaline Phosphatase (1:50, Abcam), 
ant i- lysozyme (1:500, Dako) and ant i-chromogranin A (1:1,1250, 
Abcam) were used for this study (Table 9). Appropria te secondary 
ant ibodies and ABC incubat ion was performed like before.  
 
 
Antigen Antibody 
type 
Clone Code Manufacturer Dilution 
Ki-67  Rat 
monoclonal 
MIB-5 TEC-3 Dako 1 :125 
Alkaline 
phosphatase  
Rabbit 
polyclonal 
- Ab 65834  Abcam 1:50 
Lysozyme Rabbit 
monoclonal 
A0099 Ec 3.2.1.17 Dako 1:500 
Chromogranin A Rabbit 
monoclonal 
EP1031Y Ab 15160 Abcam 1:1,1250 
Table 9. Antibodies used for organoids IHC. 
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Moreover, organoids/ spheroids were collected and transferred to 
RLT buffer ready for subsequent RNA ext raction, gene expression 
arrays and bioinformatics analyses as previously described (Figure 
11).  
 
 
 
Figure 11. Fibroblasts organoids co-culture. A Organoids were seeded on transwells in 
complete medium (EGF, Noggin, R-Spondin-1) on top of DMEM/10% FBS without 
fibroblasts. B. Organoids were seeded on transwells in medium supplemented with R-Spondin-
1, on top of DMEM/10% FBS with 1x105 fibroblasts per well from normal human colon or 
from adenomas and human CRC (central and leading edge).  
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3.5.8 Fibroblasts conditioned media and small intestine 
organoids culture  
The influence of the fibroblast on the epithelial compartment was 
assessed better by culturing organoids with fibroblasts’ condit ioned 
media.  
Wild type organoids were isolated and plated in 24 well plates for 7 
days (5 % CO2, 37 °C) in normal,  central, leading edge, SSA and 
TVA fibroblasts derivate condit ioned medium containing:  
1) R-Spondin-1(R); 
2) EGF and R-Spondin-1 (RE);  
3) EGF, Noggin, R-Spondin-1 (REN).  
These 3 different condit ions were compared to the controls that were 
cultured in organoids’ medium supplemented with EGF, Noggin, R-
Spondin-1. The media were changed every other day and on day 7,  
the number of organoids and spheroids was counted and pictures 
collected. Images were taken with a Digital DS-L1 camera (Nikon).  
 
3.6 Human colonic epithelial cell and normal fibroblast co 
culture 
The last co culture experiment was performed in order to look at the 
influence of normal and mutated epithelial cells to normal stromal 
cells. In part icular, normal and mutated human colonic epithelial 
cell lines (HCEC) were co cultured with normal fibroblasts as 
follows. 
 
3.6.1 Human colonic epithelial cell line (HCEC)  
Immortalized non-transformed adult human colonic epithelial cell 
(HCECs) generated by expression of the non oncogenic proteins 
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cyclin-dependent kinase 4 (Cdk4) and the catalyt ic component of 
human telomerase (hTERT) termed 1CT (“C” for CDK4 and “T” for 
Telomerase) (Roig et al. 2010) were provided by Pr Jerry W Shay.  
Moreover, three isogenic cell lines obtained from 1CT cells have 
been used to model different genet ic pathways to CRC (Smith et al.  
2002). In particular, 1CT expressing the KRAS V12 oncogene (1CT 
R), a shRNA directed against p53 (1CT P) and KRASV12 oncogene 
in combinat ion with a shRNA directed against p53 (1CT RP) 
(Eskiocak et al. 2011) and 1CTA, with a shRNA-mediated 
downregulat ion of APC (provided by Dr Laurence Huc) (Graillot et 
al. 2016).  
The human colonic epithelial cell used for this last co cultured 
experiment are shown in Table 10. 
Name Expressing Mutations 
1CT CDK4; hTERT non-transformed 
1CT- R CDK4; hTERT expressing Kras
V12 
1CT- P CDK4; hTERT shRNA directed against TP53  
1CT- RP CDK4; hTERT Kras
V12; TP53  
1CTA CDK4; hTERT shRNA-mediated downregulation of APC 
Table 10. Nomenclature for the Human colonic epithelial cells (HCECs). 
 
 
3.6.2 Cell Lines Maintenance  
HCECs were maintained on primaria flask in a humidified 
atmosphere with 3% CO2 at 37°C, in 4:1 high-glucose Dulbecco 
modified Eagle medium/ medium 199 supplemented with  2% FBS, 
epidermal growth factor (EGF 20ng/ml), hydrocortisone (1mg/ml),  
insulin (10mg/ ml), transferrin(2mg/ml), sodium selenite (5nM) and 
Gentamycin sulfate (50 μg/ml). In addition, 1CTA cells were 
selected by puromycin (1 μg/ml).  
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3.6.3 HCEC co culture  
Co-cultures of stromal and epithelia l cells were performed using 24 
well flat-bottomed plates. Epithelial cell lines were plated at 5x10 4  
cells on the bottom of the wells with their basal media. Normal 
fibroblasts with their medium were seeded at 5x104 cells on the 
permeable membrane of the t issue-culture inserts which were 
introduced into the epithelial cells -containing wells. The medium 
was changed every other day and the cells were splited when 
confluent. Co cultures were maintained for 7 days at 37 ◦C and 3% 
CO2.  
On day 7, cells in the inserts or in the bottom of the wells, were 
collected and transferred to RLT buffer ready for subsequent RNA 
extract ion, gene expression arrays and bioinformatics analyses as 
previously described. 
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4. RESULTS 
 
4.1 DEG analysis  
4.1.1 DEG in human TVA and SSA epithelial and stromal 
compartment 
The first goal of this research project was to gain molecular insight  
into the molecular alterat ions associated with two key temporal 
events crit ical for cancer development and maintenance, specifically 
that of cancer init iat ion and cancer progression of the convent ional 
and the serrated pathway.  
To address the cancer init iat ing events, a cohort of SSAs (serrated 
pathway) and TVAs (convent ional pathway) with neighboring 
normal t issue from pat ients was collected and the global 
transcriptomes in the epithelial and stromal compartment were 
analyzed by microarrays and bioinformatic analyses.  
In this study, microarray analysis was employed because allows 
concurrent measurement of gene expression events on a genome-
wide basis.  
For the bioinformatic analyses, the data were normalized and four 
lists of different ially expressed gene (DEG) were generated by 
comparing SSA epithelial crypt (n=11) RNA expression with 
adjacent normal crypts (n=16); TVA epithelial GEP (n=6) with 
corresponding adjacent normal (n=16); SSA stromal GEP (n=7) with 
normal GEP stroma (n=13); TVA stroma (n=5) with normal 
counterpart (n=13) (Table 11).  
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Comparison Group A Group B Sig Genes 
(FDR<0.1;LOGF
C>0.1) 
Epi_SSA 
Versus 
Normal 
Colon_Epithelium_SSA 
(N=11) 
Colon_Epithelium_Normal  
(N=16) 
275 
Strom_SSA 
Versus 
Normal 
Colon_Stroma_SSA 
(N=7) 
Colon_Stroma_Normal 
(N=13) 
104 
Epi_TVA 
Versus 
Normal 
Colon_Epithelium_TVA 
(N= 6) 
Colon_Epithelium_Normal 
(N=16) 
337 
Strom_TVA 
Versus 
Normal 
Colon_Stroma_TVA 
(N=5) 
Colon_Stroma_Normal 
(N=13) 
26 
Table 11. Different comparisons and groups used for DEG profile. 
 
 
Human serrated and tubulovillous polyps show marked variability in 
the different ially expressed genes in both the epithe lial and stromal 
compartments (Figure 12).  
The heatmap showed no overlap between the stromal gene 
expression profiles of the different polyp types, indicat ing that  
different epithelial (epi)mutations provoke variable stromal gene 
dysregulat ion in different polyp subtypes (Figure 12A). 
Venn diagrams show that stromal gene expression varies 
considerably between the different polyp subtypes with a 
comparat ively greater number of different ially expressed genes 
(DEG) in serrated lesion stroma. In fact, DEG in t he SSAs were 274 
in the epithelium and 103 in the stroma with just 1 gene shared by 
both tissues (Figure 12B) suggest ing adequate separat ion o f 
epithelial and stromal component. Moreover, t he number of genes 
that were ident ified as different ially expressed  in the epithelia l 
compartment was 284 for the TVA and 222 for the SSA with a n 
overlap of 53 genes (Figure 12C).  
In Figure 12D, the DEG in the TVAs were 329 in the epithelium and 
just 18 in the stroma with 8 overlapping genes. Figure 12E showed 
stroma gene expression from serrated polyps, has an increased 
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number of different ially expressed genes (104) than the stroma from 
TVA (26) with no overlap. Furthermore pathways enriched involved 
in the immune signaling pathways along with fibroblasts act ivated 
pathways were noticed.  
My hypothesis is that serrated lesions, usually init iated by BRAF 
mutations and methylat ion, require the recruitment of pro -
tumorigenic stroma to enable lesion progression. In contrast, 
tubulovillous adenomas are init iated by epithelial mutations that  
disrupt Wnt signaling (such as APC) and this is sufficient to drive 
tumorigenesis, irrespect ive of stromal influences.  
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Figure 12. TVAs and SSAs epithelial and stromal gene expression. A) Heatmap showing 
heterogeneity of differentially expressed genes in the TVAs and SSAs stroma. B-E Venn 
diagrams B) DEG in the SSAs. C) DEG in the epithelium. D) DEG in the TVAs. E) DEG in 
the stroma. (FDR 0.1; Log FC>0.1).  
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4.1.2 DEG in mouse epithelial and stromal compartments  
DEG analysis was performed in mice models of adenomas with the 
same purpose to invest igate the transcriptome in the epithelial and 
stromal compartments.   
The two mouse models that mimic very closely the mutat ions that  
occur in human SSA and TVA adenomas used in this study, were 
VillinCreERT2; Apc fl / fl (to mimic human TVAs precursors lesions) 
and VillinCreERT2 ; BrafV600E (to mimic human SSAs precursors 
lesions).  
The Venn diagrams show the up and downregulated DEG in 
VillinCreERT2; Apc fl / fl and VillinCreERT2 ; BrafV600E in the different  
tissue compartment compared to the wild type control mice. There is 
a significant difference between the number of genes expressed, 
posit ively or negat ively, in the epithelium compared to the stroma in 
both, VillinCreERT2 ; BrafV600E and VillinCreERT2; Apc fl/ f l mice 
(Figure 13).  
This results confirm what seen in the human polyps analysis: the 
genes up regulated in the stromal compartment are much more in the 
VillinCreERT2; BrafV600E mouse compared to VillinCreERT2; Apc fl / f l  
mice. 
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Figure 13.Venn diagrams showing the DEG in VillinCreERT2; BrafV600E (braf) and 
VillinCreERT2; Apc fl/fl (apc) mice models in the epithelial (Epi) and stromal compartment 
(Stroma).Overlaps FDR <0.05; Log FC>1. 
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4.1.3 Mouse and human DEG comparisons 
Next, the human and mice result s were compared to see if the mice 
models, employed in this study, were good models.  
As shown in Figure 14 by the Venn diagrams, there is no similitude 
between the DEG found in human and in mice. In fact, the shock 
effect of pan intest inal changes caused by the induct ion, determined 
the loss of the epithelium in favor of the stroma with a consequent  
increment of the stromal genes expression.  
In conclusion, the mouse model used for this study is not a good 
model of human polyp format ion.  
 
 
A 
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Figure 14. Venn diagrams representing VillinCreERT2; BrafV600E (braf) and 
VillinCreERT2; Apc fl/fl (apc) mice and human polyps (TVA, SSA) DEG comparisons. A) 
Up and down regulated genes in the epithelial (Epi) compartment. B) Up and down regulated 
genes in the stromal (Stroma)compartment. Overlaps FDR <0.05; Log FC>1. 
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4.2 CAFs 
The preliminary results show that the genes expressed in polyps 
stromal compartment are more and different compared to the 
epithelial compartment. I t has been shown that altered stroma can 
influence cancer development and progression (Bissell et al. 1982, 
Bissell & Hines 2011). Moreover, epithelial -mesenchymal cross talk 
plays a vital role in colorectal neoplasia init iat ion and progression 
and that variable contribut ion and importance of the different tissue 
compartments underpins some of the differences in both polyp and 
tumor subtype biology.  
Thus, in order to elucidate the role of the stroma in CRC init iat ion 
and progression, the most abundant cell-type of the stroma, 
carcinoma-associated fibroblasts (CAFs), were isolated and 
employed for in vitro studies.  
 
4.2.1 Primary culture 
Cell or tissue culture techniques have provided numerous pivotal 
informat ion to understand the basic biology of cancer al lowing 
cancer cells to be maintained outside the body. It was originally 
developed in the middle of 20th century (Langdon 2003) when 
“HeLa” was the first established cell line of human cancer 
originated from surgical pathology specimen of uterine cervical 
carcinoma from African American pat ient Henrietta Lacks in 1951 
(Hsu et al. 1976). Carcinoma cell lines have been established very 
important tools to evaluate in depth the biochemistry and molecular 
biology associated with individual cancer types and have contributed 
enormously to our understanding of normal as well as malignant cell 
physiology (Langdon 2003).  
Thus, primary culture of the whole cancer tissue derived from 
surgery or biopsy can indeed provide very important informat ion to 
our understanding o f cancer t issue microenvironment. However, it  is 
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pract ically impossible to reproduce the cancer microenvironment  
using the cancer cell line alone in in vitro analysis.  
 
4.2.2 Fibroblasts isolation 
In order to assess the influence of fibroblast and epithel ial cell 
compartments on each other, I have optimized a protocol for the 
isolat ion and culture of fibroblasts from normal and neoplast ic 
(polyp and cancer) biopsy samples.  
Fibroblasts were successfully obtained from normal colonic mucosa 
(n=16), adenocarcinomas (SSAs (n=5), TVAs (n=6) and from 16 
CRCs colonic t issue (CMS2 and CMS4) (CENTRALs (n=7) and 
LEADING EDGEs (n=9) out of a total of 50 samples collected.  
The major reasons for unsuccessful culture were bacterial 
contaminat ion and insufficient material.  Intest inal endoscopic 
biopsies contain a small amount of tissue and can be easily 
contaminated by common intest inal flora, the manual management  
of the endoscope and endoscopic forceps, and their passage through 
the endoscopic channel.  
Cultures were monitored for the appearance of highly adherent  
stromal cells with typical fibroblast ic morphology. Fibroblasts start  
to appear after 4 days (Figure 15) and they could be kept in culture 
unt il cell passage number 18 (P18). Stromal cultures were expanded 
and stored for future experiments.  
All experiments were performed using stromal cells from passage 3.  
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Figure 15. Cellular growth from a chopped and enzymatically digested fragment of 
endoscopic duodenal biopsy at different times after seeding (7-10 days) and at passage 1 in 
culture (12 days); (100 × magnification, upper panel and 200 x magnification, bottom panel).  
 
 
 
4.2.3 Characterization of human fibroblast primary cultures  
4.2.3.1 Morphological features  
The fibroblast cell populat ion was first verified by cell morphology 
under the microscope.  
The established primary fibroblast cell cultures grew as a monolayer 
of cells and showed the typical fibroblast -like features, with 
spindle-like shapes and elongated projections. The CAFs were 
slight ly more slender than the normal fibroblasts but without 
significant differences. Human normal, adenoma and tumor derived 
colon fibroblasts presented as large mesenchymal cells,  
characterized by an abundant cytoplasm provided with man y cellular 
extensions. Figure 16 shows the morphology of isolated fibroblasts. 
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Figure 16. Morphological features. Representative microscopic fields showing cancer-
associated fibroblasts. At passage 4 morphologies of CAFs were dendroidal-spindle-shaped. 
Top: low magnification; bottom: high magnification. 
 
4.2.3.2 Immunophenotyping of stromal cell primary cultures  
 
Immunocytochemistry 
At cell passage 5, the purit ies of the various fibroblast populat ions 
were verified through immunostaining by detection of specific 
fibroblast biomarkers.  
For the immunocytochemistry (ICC) experiments, the following 
primary ant ibodies have been used: ant i-viment in, ant i-α-SMA, ant i-
desmin and epithelial types were carefully excluded performing ant i-
human cytokeratin 20 immunocytochemistry.  
For fibroblast cultures derived from normal and cancerous colon 
tissues, immunocytochemical assays revealed that they highly 
expressed the fibroblast ic marker viment in,  a common mesenchymal 
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cytoskeletal marker and the smooth muscle cell marker desmin. Very 
few cytokerat in-posit ive cells were detected which may be due to 
epithelial-mesenchymal transit ion.  
In the present study, all the tested fibroblasts express the 
myofibroblast α-SMA marker. During the tumorigenesis process,  
stromal fibroblasts acquire some of the characterist ics of smooth 
muscle cells that specifically express α-SMA. This result  indicates 
that the isolated CAFs contain a high proportion of myofibroblasts.  
This high expression of α-SMA in cancer stromal cells is in 
agreement with a previous study (Orimo et al. 2005).  
None of the used ant ibody showed a specific pattern between the 
five types of fibroblasts, indicat ing that although they were good 
mesenchymal markers, they did not discard between normal 
fibroblasts and CAFs (Figure 17). 
      
Figure 17. Immunostaining characteristics of primary fibroblastic cells. All the primary 
fibroblastic cells strongly expressed fibroblastic markers vimentin, desmin and α-SMA but 
were negative for epithelial cell marker cytokeratin. (40 × magnification, upper panel; 100 × 
magnification, middle panel and 200 x magnification, bottom panel). 
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4.2.3.3 Identifying Fibroblasts in paraffin-embedded tissues 
In the present study, immunostaining analysis for stromal markers 
was used to check the localizat ion of the fibroblast in paraffin-
embedded t issue and in part icular, in the crypt -villi axis.  In order to 
visualize fibroblasts in the colonic t issue specimens by light 
macroscopy mouse and human paraffin sect ions were analized.  
 
Mouse tissue sections 
In normal wild type C57Bl/6J mouse the sect ions show the normal 
cell morphology at the crypt bases and villi t ips. Cytokerat in-
posit ive cells show epithelial cells of the crypts and villi.  
Pericryptal myofibroblasts and nonpericryptal stromal cells 
(fibroblasts) have similar morphologic appearance (hematoxylin -
eosin). Muscularis mucosae cells and pericryptal myofibroblasts are 
both α-SMA and desmin posit ive. Diffuse expression of viment in by 
both pericryptal and nonpericryptal stromal cells is evident along 
the SB1, SB2, SB3 and colon sect ions but it  is not present in the 
muscularis mucosae. Networklike connect ions are are easily 
discernible and demonstrated between the αSMA posit ive pericryptal 
myofibroblasts, the non pericryptal stromal cells and the muscularis 
mucosae (Figure 18).  
In VillinCreERT2 ; Apc fl / fl mouse, the histology revealed disturbed 
crypt-villi architecture and the strong presence of the stroma. 
Cytokeratin-posit ive cells show epithelial cells of the crypts and 
villi. Morphologically, the small bowel sections (SB1, SB2, SB3) 
show ectopic crypts and large polyps are evident in the colon. 
Pericryptal myofibroblasts and nonpericryptal fibroblasts have 
similar morphologic appearance (hematoxylin-eosin). Muscularis 
mucosae cells and pericryptal myofibroblasts are both α-smooth 
muscle act in posit ive. Furthermore, muscularis mucosae, pericryptal 
and nonpericryptal stromal cells are posit ive for desmin. Of note the 
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striking absence of viment in posit ivity in t he muscularis mucosae 
(Figure 19). 
VillinCreERT2; BrafV600E mouse histology revealed the loss of crypts 
architecture. Cytokeratin-posit ive cells show epithelia l cells of the 
crypts and villi.  In the colon, pedunculated colonic adenomas have 
central dysplast ic areas with a sharp cut off between enclosing 
serrated epithelium. Morphologically, all the small bowel sect ions 
(SB1, SB2, SB3) show prominent serrations, branching crypt with 
basilar dilatat ion and asymmetric proliferative zone. Pericryptal 
myofibroblasts and nonpericryptal stromal cells (fibroblasts) have 
similar morphologic appearance (hematoxylin-eosin). Muscularis 
mucosae cells and pericryptal myofibroblasts are both α-smooth 
muscle act in posit ive. Muscularis mucosae, pericryptal and 
nonpericryptal stromal cells are also positive for desmin whereas 
only pericryptal and nonpericryptal stromal cells are posit ive for 
viment in which is not expressed in the muscularis mucosae (Figure 
20). 
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Figure 18. Step sections of normal wild type C57Bl/6J mouse proximal small bowel (SB1), 
mid-small bowel (SB2), distal small bowel (SB3) and colonic mucosa showing the distinctly 
different immunophenotypic characteristics of the muscularis mucosae and interstitial stromal 
cells of the lamina propria. Nuclei are stained blue with hematoxylin. Antibody staining is 
shown in brown from DAB plus substrate (original magnification x 200). 
122 
 
 
Figure 19. Step sections of VillinCreERT2; Apcfl/fl mouse proximal small bowel (SB1), mid-
small bowel (SB2), distal small bowel (SB3) and colonic mucosa showing the distinctly 
different immunophenotypic characteristics of the muscularis mucosae and interstitial stromal 
cells of the lamina propria. Nuclei are stained blue with hematoxylin. Antibody staining is 
shown in brown from DAB plus substrate (original magnification x 200). 
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Figure 20. Step sections of VillinCreERT2; Braf V600E mouse proximal small bowel (SB1), mid-
small bowel (SB2), distal small bowel (SB3) and colonic mucosa showing the distinctly 
different immunophenotypic characteristics of the muscularis mucosae and interstitial stromal 
cells of the lamina propria. Nuclei are stained blue with hematoxylin. Antibody staining is 
shown in brown from DAB plus substrate (original magnification x 200). 
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Human tissue sections 
H&E staining allows seeing the normal colonic t issue, SSA with 
epithelial infoldings and ectopic crypt format ion.  TVA staining 
shows diffuse high grade dysplasia. In CRCs paraffin sect ions, it  is 
shown disrupted crypts and villi structure compared to the normal 
crypts and the infiltrat ion of the lamina propria by tumor cells.  
Cytokeratin-posit ive cells show epithelial cells of the crypts and 
villi, in the disorganized adenomas and in the chaotic CRCs 
parenchimas.  
Diffuse expression of α-smooth muscle act in by muscolaris 
mucosae, pericryptal myofibroblasts and nonpericryptal stromal 
cells with direct connect ions between the pericryptal myofibroblasts 
and the muscularis mucosae is evident in normal mucosa, adenomas 
and CRCs. Immunohistochemical staining of desmin expression by 
both pericryptal and nonpericryptal cells  is seen as well as the 
viment in ant ibody in the stromal cells of the lamina propria (Figure 
21) 
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Figure 21. Representative sections from human colon, SSA, TVA, and three different CRCs 
(CRC1, CRC2, CRC3) showing the distinctly different immunophenotypic characteristics of 
the muscularis mucosae and interstitial stromal cells of the lamina propria for H&E (A), 
cytokeratin 20 (B), α-SMA (C), desmin (D) and vimentin (E). Nuclei are stained blue with 
hematoxylin. Antibody staining is shown in brown from DAB plus substrate (original 
magnification x 200). 
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4.2.3.4 Genetic analisys 
 
qRT-PCR  
Next, the real nature of the isolated fibroblasts was further checked 
by qRT-PCR. 
In part icular, the expression of the stromal marker viment in was 
checked in the different isolated fibroblast from passage 5 to 
passage 13 (P5-13). All the analyzed fibroblasts strongly expressed 
the marker viment in (Figure 22), confirming what seen in the 
immunocytochemistry analysis.  
 
 
 
Figure 22. Relative expression of specific mesenchymal marker such as vimentin in fibroblasts 
from passage 5 to 13.  
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Passage-dependent variations of human colon fibroblast in culture  
The use of cultured fibroblasts made it possible to undertake a more 
detailed chronologic study of age-dependent variat ions induced in 
mesenchymal cells maintained in culture. It has been shown that in 
MCF-7 cell line there were some karyotype differences, which is 
generally considered due to the differences in cell passage number 
and maintenance or culture condit ions among different laboratories 
(Wenger et al. 2004).  
In order to see if the culture condit ions (early primary cultures and 
late primary cultures) have caused possible phenotypic and 
funct ional alterat ions on the isolated colon fibroblasts, gene 
expression profile was performed. Such informat ion is important for 
devising experimental models of physio pathologic relevance.  
Gene expression RNA microarray analysis for normal (n=3), SSAs 
(n=3), TVAs (n=3) and CAFs (Central n=3 and Leading edge n=3) 
pairs of early passage (P3-6) and late passage (P16-17) was 
performed. Raw data from Illumina gene expression arrays was 
processed after removing 2 outlier samples from init ial qualit y 
control (detect ion score of < 0.95 of the background intensity for 
majority of probes) using the VSN (variance-stabilisat ion and 
normalisat ion) algorithm. A filter was applied by taking a detect ion 
score of > 0.95 of the background intensity distribut ion for all 
samples to consider a probe detectable, result ing in a total of 24,262 
detectable probes. Different ially expressed genes between early 
(n=13) and late passages (n=15) were identified using Student’s t -
test by running “ttest2” command in MATLAB®. Unsupervised 
hierarchical clustering of the 24,262 genes was allowed and it  is 
shown in the heat map (Figure 23).  
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Figure 23. Hierarchical clustering heat map of the genes based on custom gene sets with 
significant differentially expressed changes with t-test adjusted P-values <0.05, a fold-change 
cut off ≥1.5, and FDR<5%. Each column represents a sample; each row refers to a gene. The 
dendrograms that determine the ordering of the rows (genes, left side) and columns (samples, 
upper side). The color bar shows the fold change and corresponding color depth: red, up-
regulated (ratio ≥1.5); green, down-regulated (ratio <1.5); and black, unchanged. 
 
 
It seems that the major difference seen in the cultured fibroblasts is  
due to the different types of fibroblast analized, confirming the 
heterogeneous origin of the CRC derived fibroblast populat ion. 
Stable gene expression changes in CAFs may be due to epigenet ic 
changes (Hu et al. 2005) versus somatic mutations (Kurose et al.  
2002, Weber et al.  2006). It is now known that somatic mutations in 
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the DNA sequence of CAFs are rarely, if ever, encountered 
(Campbell et al. 2009, Jiang et al. 2008) and thus, the acquisit ion of 
tumor-promoting act ivit ies by CAFs, in part, are due to epigenet ic 
alterat ions in the DNA (Hu et al. 2005, Mitra e t al. 2012). 
 
Comparison of gene expression patterns in Adenomas, Cancer 
stroma and Normal fibroblasts  
Next the global transcriptome of resident fibroblasts in the normal 
colon mucosa (NF) versus adenomas and CAFs in human colorectal 
cancer was analyzed. The different ially expressed genes for each 
experimental group are shown in the Venn diagrams. There is a 
significant difference in the DEG, between normal fibroblasts,  
adenomas fibroblasts (SSA and TVA) and CAFs (Central and 
Leading Edge). The numbers of genes that are shared by two or 
more groups are indicated in the intersect ions (Figure 24).  
 
 
 
130 
 
 
Figure 24. Venn diagram based on the top 200 genes from each list showing the differentially 
expressed genes overlaps between Normal, Central and Leading edge fibroblasts (LE). t-test 
adjusted P-values <0.05, a fold-change cut off ≥1.5, and FDR <5%.  
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Gene Set Enrichment Analysis (GSEA) derives its power by 
focusing on gene sets, that is, groups of genes that share common 
biological funct ion, chromosomal locat ion or regulat ion.  
Genes were ranked by computing the different ial expression in the 
adenomas and CAFs versus normal fibroblasts by the Student’s t -test 
method. If mult iple probes were present for a gene, probe with the 
highest absolute different ial expression between experimental and 
normal was selected. Gene shuffling with 1,000 permutations to 
compute the P-value for the enrichment score was used.  
The analysis of each comparison revealed expression patterns 
correlated with cell proliferat ion and cell cycle regulat ion marked 
by upregulat ion of genes involved with cell cycle progression, DNA 
synthesis/repair, protein translat ion/folding, vesicles mediated 
transport and lipid transport/metabolism. Moreover, pathway 
enriched with up-regulated genes included CAFs genes list based on 
Calon et al. 2015 (Figure 25- 28). 
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Figure 25. GSEA analysis using established gene program sets of cultured fibroblasts. 
GSEA plots shown are for A) CENTRAL versus NORMAL fibroblasts, B) LEADING EDGE 
(LE) versus NORMAL fibroblasts and C) CENTRAL versus LEADING EDGE (LE) 
fibroblasts. Enrichment score is calculated using Kolomogrov-Smirnov test. Gene shuffling 
with 1,000 permutations to compute the P-value for the enrichment score was used. 
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Figure 26. GSEA analysis using established gene program sets of cultured fibroblasts. 
GSEA plots shown are for A) TVA versus NORMAL fibroblasts, B) TVA versus CENTRAL 
fibroblasts and C) TVA versus LEADING EDGE (LE) fibroblasts. Enrichment score is 
calculated using Kolomogrov-Smirnov test. Gene shuffling with 1,000 permutations to 
compute the P-value for the enrichment score was used. 
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Figure 27. GSEA analysis using established gene program sets of cultured fibroblasts. 
GSEA plots shown are for A) SSA versus LEADING EDGE (LE) and B) SSA versus 
NORMAL fibroblasts. Enrichment score is calculated using Kolomogrov-Smirnov test. Gene 
shuffling with 1,000 permutations to compute the P-value for the enrichment score was used. 
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Figure 28. GSEA analysis using established gene program sets of cultured fibroblasts. 
GSEA plots shown are for SSA versus TVA fibroblasts. Enrichment score is calculated using 
Kolomogrov-Smirnov test. Gene shuffling with 1,000 permutations to compute the P-value for 
the enrichment score was used. 
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4.2.4 Modeling stromal- epithelial interactions 
Tumor/cancer stromal cells have been considered not only as a mere 
physical supporting cell of the parenchymal or carcinoma cells but 
also funct ional or regulatory cells in tumor/cancer 
microenvironment. Therefore, endocrine, autocrine and paracrine 
interact ions between parenchymal and stromal cells are considered 
pivotal for metastasis,  proliferat ion and angiogenesis in CRC 
microenvironment.  
As a matter of fact, cell lines cannot recapitulate the complex spat ial 
(3D) organizat ion of the intest inal epithelium. Furthermore, cell 
lines have undergone significant molecular changes to become 
immortal and do not represent all intest inal subsets, hence do not 
represent the in vivo situat ion accurately.  
In recent years, paradigm shift from two-dimensional (2D) to 3D 
cell culture techniques have been developed rapidly. 3D culture 
affects cell funct ions and behaviors including morphology and gene 
expression in a similar fashion to the in vivo response.  
Recent ly, Sato et al. presented a novel method that allows long-term 
culture of isolated intest inal crypts or intest inal stem cells (Sato & 
Clevers, 2013). This method takes advantage from the presence of 
intest inal stem cells in the crypts and makes use of a mixture of 
extracellular matrix proteins (Matrigel) that allows three-
dimensional growth. Supplemented with the appropriate growth 
factor cocktail (epidermal growth factor, Noggin, R-spondin-1) and 
cultured in a three-dimensional extracellular matrix, these intest inal 
stem cells are capable of developing into organoids, displaying 
many important funct ions of the normal intest inal epithelium (mini -
guts). Of note, the supplemented growth factors in the culture 
medium are ident ical with the signals that regulate intest inal stem 
cell niches in vivo (Sato et al. 2011a).  
In part icular, Wnt signaling is a pivotal requirement for crypt 
proliferat ion, (Korinek et al. 1998, Kuhnert et al. 2004) and the Wnt 
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act ivator R-spondin1 induces dramatic crypt hyperplasia in vivo 
(Kim et al. 2005). It has been shown that R-spondin-1 is a ligand for 
Lgr5, a marker for intest inal stem cells (Barker et al. 2007) and an 
essent ial factor to activate Wnt signal in intestinal crypts (de Lau et 
al. 2011, Sato et al. 2011a). Second, epidermal growth factor (EGF) 
signaling is associated with intest inal proliferat ion (Dignass & 
Sturm 2001). Third, transgenic expression of Noggin induces 
expansion of crypt numbers (Haramis et al. 2004). Fourth, isolated 
intest inal cells undergo anoikis outside the normal t issue context 
(Hofmann et al. 2007). Under this culture condit ion (R-spondin-1, 
EGF, and Noggin in Matrigel), small intest inal organoids can be 
ever-expanding and display all hallmarks of the small intest inal 
epithelium in terms of architecture, cell type composit ion, and self -
renewal dynamics (Sato et al.  2011a). 
Similar to the intest inal epithelium, stem cells and highly 
proliferat ive transit amplifying cells reside in the crypt -like domain 
of the organoids (Figure 29). These stem cells are able to 
different iate in to all intest inal epithelial cells (ente rocytes, Paneth 
cells, Goblet cells, enteroendocrine cells, but also stem and 
progenitor cells), as shown in vivo and in culture (Sato et al. 2009).  
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Figure 29. Schematic image of an intestinal organoid. All epithelial cell types normally 
present in vivo are also present in the cultured intestinal organoids. Secretion of mucins into the 
luminal space and lysozyme production by Paneth cells illustrate the functionality of this 
epithelium. From McCracken et al. 2011. 
 
Intratumoral fibroblast ic stromal cel ls are heterogeneous in 
individual pat ients. Therefore, the co culture system makes it  
possible to study epithelial–stromal interactions and vice versa 
through maximum simulat ion to in vivo microenvironment of CRC.  
Thus, in order to assess the paracrine e ffect of secreted signaling 
pathway cross-talk between t issue compartments on each other,  
small intest inal mouse crypts were co cultured in combinat ions with 
human normal, adenoma (SSA and TVA) and neoplasia associated 
(Central and Leading Edge (LE) fibroblasts.  
When isolated crypts were cultured in matrigel and media 
supplemented with all the growth factors, they closed and formed 
organoids - transparent sphere-like- structures within the first hours 
of culture. On day 5, the spheres started to bud, and a fter 7 days,  
organoids with numerous crypt -like structures were formed.  
Instead, the isolated crypts co cultured on top of normal, adenomas 
and cancer associated fibroblasts in medium supplemented with R-
spondin-1 (which is crucial for organoid culture) and lacking in 
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Noggin and EGF, in addit ion to adult -type minigut organoids, a 
proportion of hollow spheres (hereafter referred to as ‘‘sphero ids’’) 
were generate. This spheroid phenotype was not seen in the controls 
that received all the growth factors (Figure 30). 
It seems that the fibroblast supported the cross-species generat ion of 
normal mouse epithelial organoids and developed spheroids 
organoids, indicat ing a phenotype modulat ing effect of the 
underlying fibroblasts (Figure 31). 
Mustata et al. concluded that spheroids are made of poorly 
different iated intest inal cells with progenitor/stem cell 
characterist ics different from those of adult crypt base columnar 
cells (CBCs) and that fetal spheroids have the potential to generate 
adult-type CBCs. Spheroids cells correspond to incompletely 
caudalized progenitors (Mustata et al. 2013).  
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Figure 30. Phase contrast images of developing mouse intestinal crypts into organoids or 
spheroids in culture from day 1 to 7. A. Macroscopic image of the co culture spheroids 
development after crypt isolation; B. Organoid in culture with all the growth factors (EGF, 
Noggin, R Spondin1) from isolation (DAY 1) to mature organoid 7 days after crypt isolation, 
ready to be passaged (note the accumulated debris of dead cells in the lumen of the organoid). 
(original magnification x 200).  
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Figure 31. Ex vivo co culture of fibroblasts and mouse small intestine mini gut generates 
mixed populations of spheroids and organoids. Quantification of the percentage of spheroids 
and organoids obtained at day 7 in 3 different experiments. 
 
4.2.4.1 Characterization of small intestinal organoids 
After the intest inal villi had been co cultured for 7 days and had 
grown into organoids buddy or spheroid structures, they were 
collected and different immunostainings were performed.  
In part icular, H&E staining showed that the organoid were 
composed of a monolayer of polarized columnar epithelial cells.  
Alcian-blue staining for goblet cells revealed presence of mucus 
producing cells and the secret ion of mucus into the lumen. Besides 
different iated zones characterized, for example, by the presence of 
mucus producing cells, in small intest inal organoids proliferat ive 
zones could be dist inguished. Moreover, lysozyme staining show the 
localizat ion of Paneth cells, chromogranin A the endocrine cells and 
Alkaline P (Phosphatase) revealed the presents of the enterocytes  
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Interest ingly, Ki-67 (a non-histone nuclear protein detected in the 
G1 through M phase of cell cycle staining) staining shows that cells  
with proliferat ive act ivity seemed to be localized along the crypts in 
the control whereas in the co cultured spheroids, they are distributed 
all around the spheroid structure (Figure 32). 
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Figure 32. Mouse intestinal organoid cell type composition. Phase contrast images of 
spheroids and organoids (note the accumulated debris of dead cells in the lumen of the 
organoids). H&E staining. Markers of the different cell types were used to show 
differentiation. Alcian Blue staining (blue) for goblet cells, Chromogranin A (brown) for 
enteroendocrine cells, Alkaline phosphatase (brown) for mature enterocytes, and and Ki-67 
(brown) for the evaluation of mitotic activity staining of small intestine organoids (original 
magnification x 200). 
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Microarray analysis and gene expression arrays were performed to 
better characterized co cultured organoids /spheroids. In particular,  
different ially expressed genes in the experimental groups (2x 
normal, 2x central,  2x leading edge (LE), 2x SSA and 2x TVA) were 
contrasted with the controls (2x control (REN). 
The Venn diagrams based on the top 200 genes, show the 
different ially expressed genes between the different experimental 
groups (Figure 33). Of note, the number of different iated expressed 
genes in the SSA and TVA co cultured organoids is significant  
higher compare to the others comparisons (Figure 33 B).  
The hierarchical clustering heat maps reveal that by looking to the 
co cultured organoids with Normal, Central and Leading edge (LE) 
fibroblasts, there is an upregulat ion of the genes implicated in 
stemness and proliferat ion. In the co cultured organoids with Central 
and LE fibroblasts, there is a down regulat ion of the genes involved 
in different iat ion whereas no differences are evident considering the 
apoptotic genes expression (Figure 34).  
Gene Set Enrichment Analysis (GSEA) confirmed what seen in the 
heat maps. An enrichment was seen in the proliferat ive or transit  
amplifying pathways (DNA replicat ion, DNA repair, RNA 
processing) and in the stem cells gene expression related pathway 
(Figure 35).  
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Figure 33. Venn diagrams showing the differentially expressed genes overlaps in A) 
NORMAL, CENTRAL, LEADING EDGE, B) SSA and TVA co cultured organoids compared 
to organoids mono cultured (REN). t-test adjusted P-values <0.05, a fold-change cut off ≥1.5, 
and FDR <5%.  
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Figure 34. Hierarchical clustering heat map of the genes based on 4 custom gene sets with 
significant differentially expressed changes with t-test adjusted P-values <0.05, a fold-change 
cut off ≥1.5, and FDR<5%. Each column represents a sample; each row refers to a gene. The 
color bar shows the fold change and corresponding color depth. Gene expression changes with 
respect to median changes are denoted by: red, up-regulated (ratio ≥1.5); green, down-
regulated (ratio <1/1.5); and black, unchanged. 
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Figure 35. GSEA analysis using established gene program sets of co cultured mouse 
organoids. GSEA plots shown are for NORMAL, CENTRAL, LEADING EDGE, SSA and 
TVA co cultured organoids versus organoids mono cultured (REN). Enrichment score is 
calculated using Kolomogrov-Smirnov test. Gene shuffling with 1,000 permutations to 
compute the P-value for the enrichment score was used.  
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4.2.4.2 Fibroblasts conditioned media and small intestine 
organoids culture 
Collected fibroblasts condit ioned media was used to better 
understand the influence of the fibroblasts secreted factors to the 
organoids culture system.  
This experiment validate and confirm what see in the in the previuos 
co culture experiment. In fact, the controls that were  cultured in 
organoids’ medium supplemented with EGF, Noggin, R-Spondin-1 
(REN) formed organoids (Figure 36 A). When cultured with 
condit ioned media supplemented with EGF and R-Spondin-1 (RE), 
the spheroids phenotype was decreased (Figure 36 B, E). If the 
organoids where grown in the presents of all the growth factors, the 
size of the spheroids was increased as well as the number of 
organoids (Figure 36 C, E). Last ly, when organoids were grown in 
media supplemented by the R-Spondin-1(R) an increase in the 
number but not in the size of the spheroids was seen (Figure 36  D, 
E).  
In a similar manner to the fibroblasts,  fibroblasts secreted factors 
present in the condit ioned media supported the organoids/spheroids 
development. 
 
4.2.4.3 Assessment of organoid tissue reprogramming  
To see whether this is a co-culture dependent phenomenon or an 
imprinted change in the epithelium, the established spheroids were 
removed from the co culture and after 72 hours, in the absence of 
fibroblasts, the organoids lose the sphero id morphology and become 
“budding” organoids.  
Thus, this result demonstrates that the induced epithelial t issue 
reprogramming was lost in the absence of fibroblasts or the 
fibroblast derived secreted factors. 
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E  
Figure 36. Organoids budding and spheroids after 7 days of culture. A) Wild type 
organoids cultured in organoids’ medium supplemented with EGF, Noggin, R-Spondin-1 
(Control) B) Wild type organoids cultured in fibroblasts conditioned medium supplemented 
with EGF and R-Spondin-1 (RE); C) Wild type organoids cultured in fibroblasts conditioned 
medium supplemented with EGF, Noggin, R-Spondin-1 (REN). D) Wild type organoids 
incubated for 7 days in fibroblasts conditioned medium containing R-Spondin-1(R); (original 
magnification x100). E) Histogram showing the numbers of organoids or spheroids in each 
experimental condition.  
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4.2.5 Modeling epithelial - stromal interactions 
Each t issue compartment profoundly influences the behavior of the 
other with epithelial and stromal compartments co -evolving as 
neoplasia progresses to result in an optimal tumour 
microenvironment.  
Co culture of normal fibroblast with non-transformed human colonic 
epithelial cells and their isogenic derivat ive was performed in order 
to see how individual epithelial mutations influence stromal gene 
expression.  
The Venn diagram shows an higher number of different iated 
expressed genes in normal fibroblasts co cultured with HCEC APC 
cells (DEG=67), followed by HCEC R cells (DEG=33), HCEC RP 
cells (DEG=21) and finally non mutated HCEC OneCT (Figure 37).  
The hierarchical proliferat ion clustering heat map reveals, once 
again, the variability of the genes expression in the transit  
amplifying or proliferat ive gene list. The first difference that it  is 
evident is related to the origin of the fibroblasts (from Pat ient 1 and  
2). Moreover, APC epithelial mutated cells seems to cause a 
negat ive regulat ion of the genes expressed by the fibroblasts 
whereas KRAS alone (P) or in combinat ion with TP53 (PR), cause a 
posit ive regulat ion of the genes expression in the fibroblasts (Figure 
38).  
It  seems that, init iat ing APC and KRAS epithelial (epi)mutat ions,  
have variable effects on the underlying stroma and that confirm the  
bi-direct ional epithelial-stromal interact ion seen in vivo. However, 
the variability seen in the experiment did not allow drawing a 
definitive conclusion.  
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Figure 37. Venn diagram based on the top 200 genes from each list showing the differentially 
expressed genes overlaps in fibroblasts co cultured with HCEC APC (APC), HCEC R (R), 
HCEC RP (RP) and non mutated HCEC (OneCT) compared to normal fibroblasts (Normal). t-
test adjusted P-values <0.05, a fold-change cut off ≥1.5, and FDR <5%.  
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Figure 38. Hierarchical clustering heat map of the genes based on 4 custom gene sets with 
significant differentially expressed changes with t-test adjusted P-values <0.05, a fold-change 
cut off ≥1.5, and FDR<5%. Each column represents a sample; each row refers to a gene. The 
color bar shows the fold change and corresponding color depth. Gene expression changes with 
respect to median changes are denoted by: red, up-regulated (ratio ≥1.5); green, down-
regulated (ratio <1/1.5); and black, unchanged. 
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CONCLUSIONS 
 
The focus of the majority of studies regarding colorectal cancers has 
been the genet ic abnormalit ies of the cancer cell itself, treat ing 
colorectal tumorigenesis as a cell-autonomous process governed 
exclusively by the abnormal cancer genes (Calvert & Frucht 2002, 
Chang et al. 2000, Oving & Clevers 2002, Lin et al. 2002, 
Frederiksen et al. 2003, Jubb et al. 2003). However, it  is becoming 
evident that, if clinically relevant discoveries are to be  made in 
cancer biology and treatment, emphasis needs to be refocused to the 
“ent ire” tumor, which includes the epithelial cancer cells and 
surrounding react ive stromal components.  
Recent analysis has demonstrated that in cancer, stromal gene 
dysregulat ion contributes more to poor prognostic molecular 
signatures than the epithelium itself (Calon et al. 2015, Isella et al.  
2015), highlight ing the important influence of the tumor 
microenvironment on cancer epithelial cell behavior. What is less 
clear is whether these dynamic and important mesenchymal changes 
arise react ively, in response to invasion by malignant epithelium, or 
occur earlier and have a role in driving lesion init iat ion and 
progression.  
Moreover, the relat ive importance of the epithelial and s tromal 
tissue compartments varies between different tumour subtypes and 
this contributes to the observed clinical and molecu lar heterogeneity 
of CRC (Calon et al. 2015, Isella et al.  2015). However, the role of 
the stroma in different precancerous pathologies and in CRC, is not 
clear. Furthermore, epithelial and stromal separat ion is technically 
difficult  in established tumours prevent ing insight into the t issue 
compartmental origin of the disrupted gene expression signatures.  
Thus, the main goal of this thesis has been to gain molecular insight 
into the development of CRC. Preliminary results have shown that in 
SSAs and TVAs, the transcriptome of the stromal compartment is 
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very different from the epithelium. In particular, in the SSAs, that  
are the precursors of the serrated adenocarcinomas, the number of 
different ially expressed genes in the stroma was greater compared to 
that found in the TVAs, the precursor lesions of the convent ional 
adenocarcinomas. This led to the conclusion that serrated lesions,  
usually init iated by BRAF mutat ions and methylat ion, require the 
recruitment of pro-tumorigenic stroma to enable lesion progression. 
In contrast, tubulovillous adenomas are init iated by epithelia l 
mutations that disrupt the Wnt-β-catenin signaling pathway (such as 
APC) and this is sufficient to drive tumourigenesis,  irrespect ive of 
stromal influences.  
Unfortunately, the different ially expressed genes found in the 
epithelial and stromal compartment of VillinCreERT2; Apc fl / fl and 
VillinCreERT2; BrafV600E mouse models used in this study, were not 
comparable to those found in human adenomas showing the 
limitat ions of these two mouse models in mimicking genomic 
alterat ions in the development and progression of CRC.  
The study of experimental colon carcinogenesis in rodents has a 
long history, dat ing back almost 80 years (Krebs 1928). Numerous 
mouse models of CRC have been developed, providing insights into 
pathogenesis mechanisms, tools for discovery, validat ion of novel 
therapeut ic targets and a predict ive plat form in which to test new 
chemoprevent ion strategies (Young et al. 2013, Tong et al. 2011, 
Kobaek-Larsen et al.  2000, Rosenberg et al. 2009, Karim & Huso 
2013, Johnson & Fleet 2013).  
The hypothet ical ideal animal model should mimic the human 
disease in terms of morphology, biochemical alterat ions and 
biological behaviour (Kobaek-Larsen et al.  2000). The “ideal animal 
model” that resembles the human situat ion in all aspects does not 
exist, but available models approximate many of the characterist ics 
of human colonic carcinogenesis and metastasis. For these reasons, 
it  is important to use a specific model to address a part icular 
scient ific quest ion. CRC mouse model can be grouped as 
genet ically-engineered, chemically-induced and inoculated models.  
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Genet ically engineered mice models are useful for studying the 
importance of specific genomic alterat ions in the development and 
progression of CRC and their sensit ivity to various therapies ( Tong 
et al. 2011). The versat ility of genet ically engineered mouse models 
has not only facilitated ident ificat ion of a wide range of potent ia l 
therapeut ic targets, but also enabled the study of environmental 
factors, such as diet, on the occurrence and severity of CRC. 
Condit ional genet ic models of colorectal cancer Cre-lox technology 
is one of the most frequent ly used methods to study the very early 
stages of tumourigenesis by condit ionally inact ivat ing genes of 
interest to produce an almost endless possibility of different DNA 
disrupt ions allowing having full spat ial and temporal control over 
DNA mutat ions (El Marjou et al. 2004).   
The chemically induced mouse models mimic human sporadic 
colorectal cancer and are often used to study effect on the treatment  
or prevent ion of CRC formation (Tong et al.  2011).  
The inoculated colorectal cancer models recapitulate some features 
of colorectal cancer metastasis and are useful models for ant i-
metastat ic drug evaluat ion (Tong et al. 2011, Hung et al. 2010).  
Other models have been used to address specific quest ions like how 
aging, or alcohol consumption, or diabetes affects the risk of 
developing CRC (Karim & Huso 2013).   
There are many advantages to studying the pathogenesis of 
carcinogen-induced CRC in mouse models, including rapid and 
reproducible tumour induct ion and the recapitulat ion of the 
adenoma– carcinoma sequence that occurs in humans. Mouse models 
do recapitulate the complex, nuanced and intercompartmental 
signaling that can’t be easily achieved in vitro. Moreover, the 
availability of recombinant inbred mouse panels and the ever -
increasing number of transgenic knock-out and knock-in genet ic 
models further increase the value of the studies (Rosenberg et al.  
2009).  
These models allow test ing various therapeut ic modalit ies that  
would not be possible in humans. However, the sequence of genet ic 
events that are thought to promote tumorigenesis from epithelial 
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cells to carcinomas in humans has only partially been successful 
modelled in mice. For example, the role of oncogenes such as KRAS 
has not yet been recapitulated in mice (Karim & Huso 2013). Also, 
differences in mouse size and physiology, as wel l as variat ions in 
colon cancer that develops in mice and humans may also lead to 
translat ional limitat ions (Tong et al. 2011).  
Despite the progress made in the development of animal models of 
human CRC, there are several clear weaknesses with these models.  
First, all of the global gene delet ion and chemically-induced models 
develop cancer outside the colon; in some models colon cancer is a 
minor phenotype. As a result, long-term studies of CRC 
development are limited due to high morbidity and mortality fr om 
these other phenotypes. Induced mutat ions of the Apc gene in mice 
have provided animal models that are similar to human colon 
polyposis, although most polyps are formed in the small intest ine 
rather than in the colon (Taketo 2006). It should be noted that 
whereas FAP pat ients mainly develop polyps in the colon-rectum, 
Apc mouse models are characterized by adenomas clustering in the 
upper gastrointest inal tract, mainly in the duodenum. This 
anatomical difference between the mouse and human adenomas may 
exert a confounding effect in the analysis as duodenum and colon-
rectum represent dist inct organs (Gaspar et al. 2008).  
Second, only some of the genes relevant to human colorectal cancer 
have been modified to make mice with floxed alleles. As a result, we 
are often left with models where the cancers develop early in life 
and their development may be confounded by the anabolic 
environment of growth. In addit ion, the lack of mice with floxed 
gene alleles limits the use of tools for both intest ine-specific and 
inducible gene modificat ions in mice.  
Third, only a few of the animal models for colorectal cancer are 
relevant to natural init iat ing events that drive human colorectal 
cancer. This limits our ability to study the init ial stages of colorectal 
carcinogenesis as well as primary cancer prevent ion in animal 
models. Finally, only a few mouse models have been developed to 
study metastatic events (Johnson & Fleet 2013).  
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In summary, despite the inability of a model of CRC to completely 
recapitulate all stages of the human disease, the use and impact of 
the available models has been far reaching (Young et al.  2013). All 
of the models available have their own strengths and weaknesses,  
however it is the sheer range of mouse models available that make 
them the most versat ile tool for researchers (Johnson & Fleet 2013).  
The careful select ion of an appropriate model, allow asking 
quest ions regarding the init iat ion, progression and development of 
CRC. However, as none of these models recapitulate the process of 
CRC development in its ent irety, it  is important to use a specific 
model to address a part icular scient ific quest ion and bypass the 
imperfect ions of each individual model using supporting data gained 
from a different model. Moreover, mouse models can be combined 
with the use of computational modelling and bioinformatics in order 
to increase the impact of the data that they produce (Young et al.  
2013). With this in mind, the development  of targeted therapeut ics 
for the treatment of CRC can only be possible through the  use of a 
combinat ion of the different model plat forms (Young et al.  2013).  
Therefore developing mouse models and related methods to discover 
and validate candidate genomic CRC drivers that play an important 
role in human CRC is urgent ly needed for translat ion of CRC 
sequencing advances into new, safe and effec tive chemoprevent ives 
and treatments.   
In this study, in order to better characterize the stroma, I also 
focused on CAFs, the main cellular components of react ive stroma 
in primary and metastatic cancer. It has been shown that they play a 
key role in CRC development (Kalluri & Zeisberg 2006). In 
particular, preliminary results have shown that human normal,  
adenomas and CRC primary fibroblasts support the cross-species 
generat ion of normal mouse epit helial organoids and abrogate the 
normal requirement for Noggin and Epidermal growth factor (EGF) 
supplementat ion in the media. Moreover, they promote the  poorly 
different iated intest inal cells with progenitor/stem cell 
characterist ics in the epithelial co mpartment (spheroid phenotype).  
Furthermore, I have found that in all the co culture experiments,  
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stromal fibroblasts isolated from normal colonic t issues, precursor 
lesions and CRC promote cell proliferat ion and cell cycle regulat ion 
by upregulat ion of genes involved with cell cycle progression, DNA 
synthesis/repair, protein translat ion, vesicles mediated transport and 
lipid metabolism.  
Studying the genet ics of normal, adenomas and cancer associated 
fibroblasts can help to ident ify those genes and the pat hways 
responsible for the stromal gene dysregulation that contributes to 
poor prognostic molecular signatures seen in CRC (Calon et al.  
2015, Isella et al.  2015).   
In this study, the majority of the genes used for the transcriptome 
characterizat ions, were based on genes lists created for epithelia l 
intest inal cells. Few studies have, indeed, explored the 
characterist ics of CAFs in primary colon adenomas and cancers. The 
heterogeneity that exists in CRC pat ients was found as well in the 
isolated fibroblasts analyzed by this thesis and that didn’t allow, in 
some cases, to draw valid and reliable conclusions.  
As a matter of fact, primary culture has limitations. In fact, it  cannot 
recapitulate the complex endocrine, autocrine and paracrine 
interact ions between parenchymal and stromal cells that are 
considered pivotal for metastasis, proliferation and angiogenesis in 
CRC microenvironment. Furthermore, cell lines undergo molecular 
changes, hence do not represent the in vivo situat ion accurately.  
Indeed, RNA microarray studies provide the potential to greatly 
enhance our knowledge of the genes and pathways involved in the 
physiological responses to physiological stressors, drugs,  
environmental st imuli and in pathogenesis of diseases. Managing 
and mining the huge amount of data generated by microarray 
experiments remains a major challenge. This is because microarray 
analysis challenges the tradit ional hypothesis driven method of 
invest igat ion and shifts the emphasis towards hypothesis generat ion.  
Validat ion of microarray expression trends using a second readout 
remains a crit ical requirement. This is especially important if the 
sample size is too small to allow rigorous statist ical analysis (as 
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shown in this study). It is also worth remembering that gene 
expression studies measure mRNA levels thereby provide a snapshot 
of relat ive mRNA abundance at the t ime of measurement and no 
more. Since most genes are also highly regulated at the post -
transcript ional stage, changes in mRNA levels may not necessarily 
reflect changes at the protein level. Thus, follow-up studies in a 
larger sample will have more power to find subt le differences.    
Furthermore, the integrat ion of this technology with the appropriate 
post-microarray validat ion experiments like, for example, the power 
of mouse models, as test ing in humans is limited. Mouse models can 
be used to explain the underlying biological mechanisms found in 
this study with the purpose to better understand the role of CAFs in 
human CRC pathogenesis. Mouse studies are t ime- and cost 
effect ive and they share 99% of their genes with humans. This will 
allow drawing more confirmat ive conclusions.  
In conclusion, primary fibroblast cell cultures might in part 
represent the corresponding cancer microenvironment. Preliminary 
results, confirm that cancer cells and surrounding stroma cooperate 
in tumor angiogenesis and invasion through an act ive autocrine 
and/or paracrine fashion. Important ly,  the expression of genes 
related to angiogenesis, invasion and metastasis, cell adhesion and 
proliferat ion were altered, thus further supporting the proposed 
crit ical role of cancer stroma in providing a favorable environment  
for cancer proliferat ion and invasion. Understanding the cellular and 
molecular processes governing stromal influence on epithelial cell 
biology at all stages and in all subtypes of colorectal tumours will 
be vital to clinically risk stratify pat ients with colorectal polyps,  
ident ify novel therapeut ic targets and assist in effect ively harnessing 
the power of the endogenous immune system. Future therapies 
directed to blocking the cross-talk between stromal elements and 
epithelial cells may provide a more effect ive approach to prevent ion 
and treatment of colon cancer.  
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